{"id":"memantine","rwe":[{"pmid":"41885326","year":"2026","title":"Incidence of amyloid-related imaging abnormalities and health resource utilization in patients with Alzheimer disease receiving monoclonal antibody treatments: A real-world evidence study.","finding":"","journal":"Journal of managed care & specialty pharmacy","studyType":"Clinical Study"},{"pmid":"41877006","year":"2026","title":"Posterior insular cortex hyperactivation drives vestibular migraine and comorbid anxiety.","finding":"","journal":"The journal of headache and pain","studyType":"Clinical Study"},{"pmid":"41874250","year":"2026","title":"Comparison table: Drugs for Alzheimer's disease dementia.","finding":"","journal":"The Medical letter on drugs and therapeutics","studyType":"Clinical Study"},{"pmid":"41874248","year":"2026","title":"Drugs for dementia.","finding":"","journal":"The Medical letter on drugs and therapeutics","studyType":"Clinical Study"},{"pmid":"41863240","year":"2026","title":"Diamonds for the Mind: Exploring the Potential of Adamantane against Alzheimer's Disease.","finding":"","journal":"Mini reviews in medicinal chemistry","studyType":"Clinical Study"}],"_fda":{"id":"cf08de43-a887-40f3-a074-57ecc8d3093a","set_id":"054069b5-7aac-4106-821f-ebf7fd531b4f","openfda":{"upc":["0353746169105","0353746169303","0353746173300","0353746173102"],"unii":["JY0WD0UA60"],"route":["ORAL"],"rxcui":["996561","996571"],"spl_id":["cf08de43-a887-40f3-a074-57ecc8d3093a"],"brand_name":["Memantine hydrochloride"],"spl_set_id":["054069b5-7aac-4106-821f-ebf7fd531b4f"],"package_ndc":["53746-173-30","53746-173-60","53746-173-10","53746-169-30","53746-169-60","53746-169-10"],"product_ndc":["53746-169","53746-173"],"generic_name":["MEMANTINE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["MEMANTINE HYDROCHLORIDE"],"manufacturer_name":["Amneal Pharmaceuticals of New York LLC"],"application_number":["ANDA090041"],"is_original_packager":[true]},"version":"19","pregnancy":["8.1 Pregnancy Risk Summary There are no adequate data on the developmental risk associated with the use of memantine hydrochloride in pregnant women. Adverse developmental effects (decreased body weight, and skeletal ossification) were observed in the offspring of rats administered memantine during pregnancy at doses associated with minimal maternal toxicity. These doses are higher than those used in humans at the maximum recommended daily dose of memantine hydrochloride [see Data] . In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown. Data Animal Data Oral administration of memantine (0, 2, 6, or 18 mg/kg/day) to rats during the period of organogenesis resulted in decreased skeletal ossification in fetuses at the highest dose tested. The higher no-effect dose for adverse developmental effects (6 mg/kg) is 3 times the maximum recommended human daily dose (MRHD) of memantine hydrochloride (20 mg) on a body surface area (mg/m 2 ) basis. Oral administration of memantine to rabbits (0, 3, 10, or 30 mg/kg/day) during the period of organogenesis resulted in no adverse developmental effects. The highest dose tested is approximately 30 times the MRHD of memantine hydrochloride on a mg/m 2 basis. In rats, memantine (0, 2, 6, or 18 mg/kg/day) was administered orally prior to and throughout mating and, in females, through the period of organogenesis or continuing throughout lactation to weaning. Decreased skeletal ossification in fetuses and decreased body weight in pups were observed at the highest dose tested. The higher no-effect dose for adverse developmental effects (6 mg/kg/day) is 3 times the MRHD of memantine hydrochloride on a mg/m 2 basis. Oral administration of memantine (0, 2, 6, or 18 mg/kg/day) to rats from late gestation throughout lactation to weaning, resulted in decreased pup weights at the highest dose tested. The higher no-effect dose (6 mg/kg/day) is approximately 3 times the MRHD of memantine hydrochloride on a mg/m 2 basis."],"overdosage":["10 OVERDOSAGE Signs and symptoms most often accompanying memantine overdosage in clinical trials and from worldwide marketing experience, alone or in combination with other drugs and/or alcohol, include agitation, asthenia, bradycardia, confusion, coma, dizziness, ECG changes, increased blood pressure, lethargy, loss of consciousness, psychosis, restlessness, slowed movement, somnolence, stupor, unsteady gait, visual hallucinations, vertigo, vomiting, and weakness. The largest known ingestion of memantine worldwide was 2 grams in a patient who took memantine in conjunction with unspecified antidiabetic medications. The patient experienced coma, diplopia, and agitation, but subsequently recovered. Fatal outcome has been very rarely reported with memantine, and the relationship to memantine was unclear. Because strategies for the management of overdose are continually evolving, it is advisable to contact a poison control center to determine the latest recommendations for the management of an overdose of any drug. As in any cases of overdose, general supportive measures should be utilized, and treatment should be symptomatic. Elimination of memantine can be enhanced by acidification of urine."],"description":["11 DESCRIPTION Memantine hydrochloride, USP is an orally active NMDA receptor antagonist. The chemical name for memantine hydrochloride, USP is 1-amino-3,5-dimethyladamantane hydrochloride with the following structural formula: The molecular formula is C 12 H 21 N•HCl and the molecular weight is 215.76. Memantine hydrochloride, USP occurs as a fine white to off-white powder and is soluble in water. Memantine hydrochloride, USP is available for oral administration as oblong, film-coated tablets containing either 5 mg or 10 mg of memantine hydrochloride, USP. The tablets also contain the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose and talc. In addition the following inactive ingredients are also present as components of the film coat: D&C Yellow #10, FD&C Blue #2, FD&C Yellow #6, macrogol, polyvinyl alcohol, talc, and titanium dioxide (5 mg tablets), and iron oxide black, iron oxide yellow, macrogol, polyvinyl alcohol, talc and titanium dioxide (10 mg tablets). 1"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Memantine Hydrochloride Tablets USP, 5 mg, are supplied as orange colored, oblong, biconvex, film-coated tablets debossed “IP 173” on one side and plain on the other side. They are available as follows: Bottles of 30: NDC 53746-173-30 Bottles of 60: NDC 53746-173-60 Bottles of 1000: NDC 53746-173-10 Memantine Hydrochloride Tablets USP, 10 mg, are supplied as gray colored, oblong, biconvex, film-coated tablets debossed “IP 174” on one side and plain on the other side. They are available as follows: Bottles of 30: NDC 53746-169-30 Bottles of 60: NDC 53746-169-60 Bottles of 1000: NDC 53746-169-10 Store Memantine Hydrochloride Tablets, USP at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]."],"geriatric_use":["8.5 Geriatric Use The majority of people with Alzheimer’s disease are 65 years and older. In the clinical studies of memantine hydrochloride the mean age of patients was approximately 76; over 90% of patients were 65 years and older, 60% were 75 years and older, and 12% were at or above 85 years of age. The efficacy and safety data presented in the clinical trial sections were obtained from these patients. There were no clinically meaningful differences in most adverse events reported by patient groups ≥ 65 years old and < 65 years old."],"pediatric_use":["8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established. Memantine failed to demonstrate efficacy in two 12-week controlled clinical studies of 578 pediatric patients aged 6 to 12 years with autism spectrum disorders (ASD), including autism, Asperger’s disorder and Pervasive Development Disorder - Not Otherwise Specified (PDD-NOS). Memantine has not been studied in pediatric patients under 6 years of age or over 12 years of age. Memantine treatment was initiated at 3 mg/day and the dose was escalated to the target dose (weight-based) by week 6. Oral doses of memantine 3 mg, 6 mg, 9 mg, or 15 mg extended-release capsules were administered once daily to patients with weights < 20 kg, 20 kg to 39 kg, 40 kg to 59 kg and ≥ 60 kg, respectively. In a randomized, 12-week double-blind, placebo-controlled parallel study (Study A) in patients with autism, there was no statistically significant difference in the Social Responsiveness Scale (SRS) total raw score between patients randomized to memantine (n=54) and those randomized to placebo (n=53). In a 12-week responder-enriched randomized withdrawal study (Study B) in 471 patients with ASD, there was no statistically significant difference in the loss of therapeutic response rates between patients randomized to remain on full-dose memantine (n=153) and those randomized to switch to placebo (n=158). The overall risk profile of memantine in pediatric patients was generally consistent with the known risk profile in adults [see Adverse Reactions (6.1)] . In Study A, the adverse reactions in the memantine group (n=56) that were reported in at least 5% of patients and at least twice the frequency of the placebo group (N=58) are listed in Table 2: Table 2: Study A Commonly Reported Adverse Reactions with a Frequency ≥ 5% and Twice That of Placebo Adverse Reaction Memantine N=56 Placebo N=58 Cough 8.9% 3.4% Influenza 7.1% 3.4% Rhinorrhea 5.4% 0% Agitation 5.4% 1.7% Discontinuations due to adverse reactions a Aggression 3.6% 1.7% Irritability 1.8% 3.4% a Reported adverse reactions leading to discontinuation in more than one patient in either treatment group. The adverse reactions that were reported in at least 5% of patients in the 12 to 48 week open-label study to identify responders to enroll in Study B are listed in Table 3: Table 3: 12 to 48 Week Open Label Lead-In study to Study B Commonly Reported Adverse Reactions with a Frequency ≥ 5% Adverse Reaction Memantine N=903 Headache 8.0% Nasopharyngitis 6.3% Pyrexia 5.8% Irritability 5.4% Discontinuations due to adverse reactions a Irritability 1.2% Aggression 1.0% a At least 1% incidence of adverse reactions leading to premature discontinuation. In the randomized withdrawal study (Study B), the adverse reaction in patients randomized to placebo (n=160) and reported in at least 5% of patients and at twice the frequency of the full-dose memantine treatment group (n=157) was irritability (5.0% vs 2.5%). Juvenile Animal Study In a study in which memantine (0, 15, 30 or 45 mg/kg/day) was orally administered to rats during the juvenile period of development (postnatal days [PND] 14 through 70), delays in sexual maturation were noted in males and females at all but the lowest dose tested, and body weight was reduced at the high dose. In rats orally administered memantine as a single dose (PND 14) or three daily doses (PND 14 to 16), neuronal lesions were observed in several areas of the brain at all but the lowest dose tested. Adverse neurobehavioral effects (decreased auditory startle habituation) were observed at the high dose. The no-effect dose for developmental toxicity was the lowest dose tested (15 mg/kg/day). In a second juvenile animal study, memantine (0, 1, 3, 8, 15, 30, and 45 mg/kg/day) was orally administered to male and female rats beginning on PND 7 and continuing for various periods during postnatal development. Because of early memantine-related mortality, the 30 and 45 mg/kg/day groups were terminated without further evaluation. Apoptosis or neuronal degeneration in the brain was observed on PNDs 8 to 17 at a dose of 15 mg/kg/day. The no-effect dose for apoptosis and neuronal degeneration was 8 mg/kg/day. In animals in which memantine (0, 1, 3, 8, or 15 mg/kg/day) was orally administered on PNDs 7 to 70, adverse neurobehavioral effects (increased locomotor motor activity, increased auditory startle response and decreased habituation, and deficit in learning and memory) were observed at all but the lowest dose tested. Effects on auditory startle persisted after drug discontinuation. The no-effect dose for developmental toxicity was the lowest dose tested (1 mg/kg/day)."],"effective_time":"20230817","nursing_mothers":["8.2 Lactation Risk Summary There are no data on the presence of memantine in human milk, the effects on the breastfed infant, or the effects of memantine hydrochloride on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for memantine hydrochloride and any potential adverse effects on the breastfed infant from memantine hydrochloride or from the underlying maternal condition."],"clinical_studies":["14 CLINICAL STUDIES The effectiveness of memantine hydrochloride as a treatment for patients with moderate to severe Alzheimer’s disease was demonstrated in 2 randomized, double-blind, placebo-controlled clinical studies (Studies 1 and 2) conducted in the United States that assessed both cognitive function and day to day function. The mean age of patients participating in these two trials was 76 with a range of 50 to 93 years. Approximately 66% of patients were female and 91% of patients were Caucasian. A third study (Study 3), carried out in Latvia, enrolled patients with severe dementia, but did not assess cognitive function as a planned endpoint. Study Outcome Measures: In each U.S. study, the effectiveness of memantine hydrochloride was determined using both an instrument designed to evaluate overall function through caregiver-related assessment, and an instrument that measures cognition. Both studies showed that patients on memantine hydrochloride experienced significant improvement on both measures compared to placebo. Day-to-day function was assessed in both studies using the modified Alzheimer’s disease Cooperative Study -Activities of Daily Living inventory (ADCS-ADL). The ADCS-ADL consists of a comprehensive battery of ADL questions used to measure the functional capabilities of patients. Each ADL item is rated from the highest level of independent performance to complete loss. The investigator performs the inventory by interviewing a caregiver familiar with the behavior of the patient. A subset of 19 items, including ratings of the patient’s ability to eat, dress, bathe, telephone, travel, shop, and perform other household chores has been validated for the assessment of patients with moderate to severe dementia. This is the modified ADCS-ADL, which has a scoring range of 0 to 54, with the lower scores indicating greater functional impairment. The ability of memantine hydrochloride to improve cognitive performance was assessed in both studies with the Severe Impairment Battery (SIB), a multi-item instrument that has been validated for the evaluation of cognitive function in patients with moderate to severe dementia. The SIB examines selected aspects of cognitive performance, including elements of attention, orientation, language, memory, visuospatial ability, construction, praxis, and social interaction. The SIB scoring range is from 0 to 100, with lower scores indicating greater cognitive impairment. Study 1 (Twenty-Eight-Week Study) In a study of 28 weeks duration, 252 patients with moderate to severe probable Alzheimer’s disease (diagnosed by DSM-IV and NINCDS-ADRDA criteria, with Mini-Mental State Examination scores ≥ 3 and ≤ 14 and Global Deterioration Scale Stages 5 to 6) were randomized to memantine hydrochloride or placebo. For patients randomized to memantine hydrochloride, treatment was initiated at 5 mg once daily and increased weekly by 5 mg/day in divided doses to a dose of 20 mg/day (10 mg twice a day). Effects on the ADCS-ADL Figure 1 shows the time course for the change from baseline in the ADCS-ADL score for patients in the two treatment groups completing the 28 weeks of the study. At 28 weeks of treatment, the mean difference in the ADCS-ADL change scores for the memantine hydrochloride-treated patients compared to the patients on placebo was 3.4 units. Using an analysis based on all patients and carrying their last study observation forward (LOCF analysis), memantine hydrochloride treatment was statistically significantly superior to placebo. Figure 1: Time course of the change from baseline in ADCS-ADL score for patients completing 28 weeks of treatment. Figure 2 shows the cumulative percentages of patients from each of the treatment groups who had attained at least the change in the ADCS-ADL shown on the X axis. The curves show that both patients assigned to memantine hydrochloride and placebo have a wide range of responses and generally show deterioration (a negative change in ADCS-ADL compared to baseline), but that the memantine hydrochloride group is more likely to show a smaller decline or an improvement. (In a cumulative distribution display, a curve for an effective treatment would be shifted to the left of the curve for placebo, while an ineffective or deleterious treatment would be superimposed upon or shifted to the right of the curve for placebo). Figure 2: Cumulative percentage of patients completing 28 weeks of double-blind treatment with specified changes from baseline in ADCS-ADL scores. Effects on the SIB Figure 3 shows the time course for the change from baseline in SIB score for the two treatment groups over the 28 weeks of the study. At 28 weeks of treatment, the mean difference in the SIB change scores for the memantine hydrochloride-treated patients compared to the patients on placebo was 5.7 units. Using an LOCF analysis, memantine hydrochloride treatment was statistically significantly superior to placebo. Figure 3: Time course of the change from baseline in SIB score for patients completing 28 weeks of treatment. Figure 4 shows the cumulative percentages of patients from each treatment group who had attained at least the measure of change in SIB score shown on the X axis. The curves show that both patients assigned to memantine hydrochloride and placebo have a wide range of responses and generally show deterioration, but that the memantine hydrochloride group is more likely to show a smaller decline or an improvement. Figure 4: Cumulative percentage of patients completing 28 weeks of double-blind treatment with specified changes from baseline in SIB scores. Study 2 (Twenty-Four-Week Study) In a study of 24 weeks duration, 404 patients with moderate to severe probable Alzheimer’s disease (diagnosed by NINCDS-ADRDA criteria, with Mini-Mental State Examination scores ≥ 5 and ≤ 14) who had been treated with donepezil for at least 6 months and who had been on a stable dose of donepezil for the last 3 months were randomized to memantine hydrochloride or placebo while still receiving donepezil. For patients randomized to memantine hydrochloride, treatment was initiated at 5 mg once daily and increased weekly by 5 mg/day in divided doses to a dose of 20 mg/day (10 mg twice a day). Effects on the ADCS-ADL Figure 5 shows the time course for the change from baseline in the ADCS-ADL score for the two treatment groups over the 24 weeks of the study. At 24 weeks of treatment, the mean difference in the ADCS-ADL change scores for the memantine hydrochloride/donepezil treated patients (combination therapy) compared to the patients on placebo/donepezil (monotherapy) was 1.6 units. Using an LOCF analysis, memantine hydrochloride/donepezil treatment was statistically significantly superior to placebo/donepezil. Figure 5: Time course of the change from baseline in ADCS-ADL score for patients completing 24 weeks of treatment. Figure 6 shows the cumulative percentages of patients from each of the treatment groups who had attained at least the measure of improvement in the ADCS-ADL shown on the X axis. The curves show that both patients assigned to memantine hydrochloride/donepezil and placebo/donepezil have a wide range of responses and generally show deterioration, but that the memantine hydrochloride/donepezil group is more likely to show a smaller decline or an improvement. Figure 6: Cumulative percentage of patients completing 24 weeks of double-blind treatment with specified changes from baseline in ADCS-ADL scores. Effects on the SIB Figure 7 shows the time course for the change from baseline in SIB score for the two treatment groups over the 24 weeks of the study. At 24 weeks of treatment, the mean difference in the SIB change scores for the memantine hydrochloride/donepezil-treated patients compared to the patients on placebo/donepezil was 3.3 units. Using an LOCF analysis, memantine hydrochloride/donepezil treatment was statistically significantly superior to placebo/donepezil. Figure 7: Time course of the change from baseline in SIB score for patients completing 24 weeks of treatment. Figure 8 shows the cumulative percentages of patients from each treatment group who had attained at least the measure of improvement in SIB score shown on the X axis. The curves show that both patients assigned to memantine hydrochloride/donepezil and placebo/donepezil have a wide range of responses, but that the memantine hydrochloride/donepezil group is more likely to show an improvement or a smaller decline. Figure 8: Cumulative percentage of patients completing 24 weeks of double-blind treatment with specified changes from baseline in SIB scores. Study 3 (Twelve-Week Study) In a double-blind study of 12 weeks duration, conducted in nursing homes in Latvia, 166 patients with dementia according to DSM-III-R, a Mini-Mental State Examination score of < 10, and Global Deterioration Scale staging of 5 to 7 were randomized to either memantine hydrochloride or placebo. For patients randomized to memantine hydrochloride, treatment was initiated at 5 mg once daily and increased to 10 mg once daily after 1 week. The primary efficacy measures were the care dependency subscale of the Behavioral Rating Scale for Geriatric Patients (BGP), a measure of day-to-day function, and a Clinical Global Impression of Change (CGI-C), a measure of overall clinical effect. No valid measure of cognitive function was used in this study. A statistically significant treatment difference at 12 weeks that favored memantine hydrochloride over placebo was seen on both primary efficacy measures. Because the patients entered were a mixture of Alzheimer’s disease and vascular dementia, an attempt was made to distinguish the two groups and all patients were later designated as having either vascular dementia or Alzheimer’s disease, based on their scores on the Hachinski Ischemic Scale at study entry. Only about 50% of the patients had computerized tomography of the brain. For the subset designated as having Alzheimer’s disease, a statistically significant treatment effect favoring memantine hydrochloride over placebo at 12 weeks was seen on both the BGP and CGI-C. Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Figure 7 Figure 8"],"pharmacodynamics":["12.2 Pharmacodynamics Memantine showed low to negligible affinity for GABA, benzodiazepine, dopamine, adrenergic, histamine and glycine receptors and for voltage-dependent Ca 2+ , Na + or K + channels. Memantine also showed antagonistic effects at the 5HT 3 receptor with a potency similar to that for the NMDA receptor and blocked nicotinic acetylcholine receptors with one-sixth to one-tenth the potency. In vitro studies have shown that memantine does not affect the reversible inhibition of acetylcholinesterase by donepezil, galantamine, or tacrine."],"pharmacokinetics":["12.3 Pharmacokinetics Absorption Following oral administration memantine is highly absorbed with peak concentrations reached in about 3 to 7 hours. Memantine has linear pharmacokinetics over the therapeutic dose range. Food has no effect on the absorption of memantine. Distribution The mean volume of distribution of memantine is 9 to 11 L/kg and the plasma protein binding is low (45%). Metabolism Memantine undergoes partial hepatic metabolism. The hepatic microsomal CYP450 enzyme system does not play a significant role in the metabolism of memantine. Elimination Memantine is excreted predominantly (about 48%) unchanged in urine and has a terminal elimination half-life of about 60 to 80 hours. The remainder is converted primarily to three polar metabolites which possess minimal NMDA receptor antagonistic activity: the N-glucuronide conjugate, 6-hydroxy memantine, and 1-nitroso-deaminated memantine. A total of 74% of the administered dose is excreted as the sum of the parent drug and the N-glucuronide conjugate. Renal clearance involves active tubular secretion moderated by pH dependent tubular reabsorption. Pharmacokinetics in Specific Populations Gender Following multiple dose administration of memantine hydrochloride 20 mg daily, females had about 45% higher exposure than males, but there was no difference in exposure when body weight was taken into account. Elderly The pharmacokinetics of memantine hydrochloride in young and elderly subjects are similar. Renal Impairment Memantine pharmacokinetics were evaluated following single oral administration of 20 mg memantine hydrochloride in 8 subjects with mild renal impairment (creatinine clearance, CLcr, > 50 to 80 mL/min), 8 subjects with moderate renal impairment (CLcr 30 to 49 mL/min), 7 subjects with severe renal impairment (CLcr 5 to 29 mL/min) and 8 healthy subjects (CLcr > 80 mL/min) matched as closely as possible by age, weight and gender to the subjects with renal impairment. Mean AUC 0-∞ increased by 4%, 60%, and 115% in subjects with mild, moderate, and severe renal impairment, respectively, compared to healthy subjects. The terminal elimination half-life increased by 18%, 41%, and 95% in subjects with mild, moderate, and severe renal impairment, respectively, compared to healthy subjects. No dosage adjustment is recommended for patients with mild and moderate renal impairment. Dosage should be reduced in patients with severe renal impairment [see Dosage and Administration (2) ] . Hepatic Impairment Memantine pharmacokinetics were evaluated following the administration of single oral doses of 20 mg in 8 subjects with moderate hepatic impairment (Child-Pugh Class B, score 7 to 9) and 8 subjects who were age-, gender-, and weight-matched to the hepatically-impaired subjects. There was no change in memantine exposure (based on C max and AUC) in subjects with moderate hepatic impairment as compared with healthy subjects. However, terminal elimination half-life increased by about 16% in subjects with moderate hepatic impairment as compared with healthy subjects. No dose adjustment is recommended for patients with mild and moderate hepatic impairment. Memantine should be administered with caution to patients with severe hepatic impairment as the pharmacokinetics of memantine have not been evaluated in that population. Drug-Drug Interactions Use with Cholinesterase Inhibitors Co-administration of memantine with the AChE inhibitor donepezil hydrochloride did not affect the pharmacokinetics of either compound. Furthermore, memantine did not affect AChE inhibition by donepezil. In a 24-week controlled clinical study in patients with moderate to severe Alzheimer’s disease, the adverse event profile observed with a combination of memantine hydrochloride and donepezil was similar to that of donepezil alone. Effect of Memantine Hydrochloride on the Metabolism of Other Drugs In vitro studies conducted with marker substrates of CYP450 enzymes (CYP1A2, -2A6, -2C9, 2D6, -2E1, -3A4) showed minimal inhibition of these enzymes by memantine. In addition, in vitro studies indicate that at concentrations exceeding those associated with efficacy, memantine does not induce the cytochrome P450 isozymes CYP1A2, -2C9, -2E1 and -3A4/5. No pharmacokinetic interactions with drugs metabolized by these enzymes are expected. Pharmacokinetic studies evaluated the potential of memantine for interaction with warfarin, and buproprion. Memantine did not affect the pharmacokinetics of the CYP2B6 substrate buproprion or its metabolite hydroxy-buproprion. Furthermore, memantine did not affect the pharmacokinetics or pharmacodynamics of warfarin as assessed by the prothrombin INR. Effect of Other Drugs on Memantine Hydrochloride Memantine is predominantly renally eliminated, and drugs that are substrates and/or inhibitors of the CYP450 system are not expected to alter the metabolism of memantine. Drugs Eliminated via Renal Mechanisms Because memantine is eliminated in part by tubular secretion, co-administration of drugs that use the same renal cationic system, including hydrochlorothiazide (HCTZ), triamterene (TA), metformin, cimetidine, ranitidine, quinidine, and nicotine, could potentially result in altered plasma levels of both agents. However, co-administration of memantine hydrochloride and HCTZ/TA did not affect the bioavailability of either memantine or TA, and the bioavailability of HCTZ decreased by 20%. In addition, co-administration of memantine with the antihyperglycemic drug Glucovance ® (glyburide and metformin hydrochloride) did not affect the pharmacokinetics of memantine, metformin and glyburide. Furthermore, memantine did not modify the serum glucose lowering effect of Glucovance ® , indicating the absence of a pharmacodynamic interaction. Drugs Highly Bound to Plasma Proteins Because the plasma protein binding of memantine is low (45%), an interaction with drugs that are highly bound to plasma proteins, such as warfarin and digoxin, is unlikely."],"adverse_reactions":["6 ADVERSE REACTIONS Most common adverse reactions (≥ 5 % and greater than placebo) are dizziness, headache, confusion and constipation. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Memantine hydrochloride was evaluated in eight double-blind placebo-controlled trials involving a total of 1862 dementia (Alzheimer’s disease, vascular dementia) patients (940 patients treated with memantine hydrochloride and 922 patients treated with placebo) for a treatment period up to 28 weeks. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. Adverse Events Leading to Discontinuation In placebo-controlled trials in which dementia patients received doses of memantine hydrochloride up to 20 mg/day, the likelihood of discontinuation because of an adverse reaction was the same in the memantine hydrochloride group (10.1%) as in the placebo group (11.5%). No individual adverse reaction was associated with the discontinuation of treatment in 1% or more of memantine hydrochloride-treated patients and at a rate greater than placebo. Most Common Adverse Reactions In double-blind placebo-controlled trials involving dementia patients, the most common adverse reactions (incidence ≥ 5% and higher than placebo) in patients treated with memantine hydrochloride were dizziness, headache, confusion and constipation. Table 1 lists all adverse reactions that occurred in at least 2% of patients treated with memantine hydrochloride and at an incidence greater than placebo. Table 1: Adverse Reactions Reported in Controlled Clinical Trials in at Least 2% of Patients Receiving Memantine Hydrochloride and at a Higher Frequency than Placebo-treated Patients Adverse Reaction Placebo (N = 922) % Memantine Hydrochloride (N = 940) % Body as a Whole Fatigue 1 2 Pain 1 3 Cardiovascular System Hypertension 2 4 Central and Peripheral Nervous System Dizziness 5 7 Headache 3 6 Gastrointestinal System Constipation 3 5 Vomiting 2 3 Musculoskeletal System Back pain 2 3 Psychiatric Disorders Confusion 5 6 Somnolence 2 3 Hallucination 2 3 Respiratory System Coughing 3 4 Dyspnea 1 2 The overall profile of adverse reactions and the incidence rates for individual adverse reactions in the subpopulation of patients with moderate to severe Alzheimer’s disease were not different from the profile and incidence rates described above for the overall dementia population. Seizures Memantine hydrochloride has not been systematically evaluated in patients with a seizure disorder. In clinical trials of memantine hydrochloride, seizures occurred in 0.2% of patients treated with memantine hydrochloride and 0.5% of patients treated with placebo. 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of memantine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These reactions include: Blood and Lymphatic System Disorders - agranulocytosis, leukopenia (including neutropenia), pancytopenia, thrombocytopenia, thrombotic thrombocytopenic purpura. Cardiac Disorders - cardiac failure congestive. Gastrointestinal Disorders - pancreatitis. Hepatobiliary Disorders - hepatitis. Psychiatric Disorders - suicidal ideation. Renal and Urinary Disorders - acute renal failure (including increased creatinine and renal insufficiency). Skin Disorders - Stevens Johnson syndrome."],"contraindications":["4 CONTRAINDICATIONS Memantine hydrochloride tablets are contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation. Memantine hydrochloride tablets are contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation. (4)"],"drug_interactions":["7 DRUG INTERACTIONS 7.1 Drugs that Make the Urine Alkaline The clearance of memantine was reduced by about 80% under alkaline urine conditions at pH 8. Therefore, alterations of urine pH towards the alkaline condition may lead to an accumulation of the drug with a possible increase in adverse effects. Urine pH is altered by diet, drugs (e.g. carbonic anhydrase inhibitors, sodium bicarbonate) and clinical state of the patient (e.g. renal tubular acidosis or severe infections of the urinary tract). Hence, memantine should be used with caution under these conditions. 7.2 Use with Other N-methyl-D-aspartate (NMDA) Antagonists The combined use of memantine hydrochloride with other NMDA antagonists (amantadine, ketamine, and dextromethorphan) has not been systematically evaluated and such use should be approached with caution."],"mechanism_of_action":["12.1 Mechanism of Action Persistent activation of central nervous system N-methyl-D-aspartate (NMDA) receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of Alzheimer’s disease. Memantine is postulated to exert its therapeutic effect through its action as a low to moderate affinity uncompetitive (open-channel) NMDA receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels. There is no evidence that memantine prevents or slows neurodegeneration in patients with Alzheimer’s disease."],"pediatric_use_table":["
Adverse ReactionMemantineN=56PlaceboN=58
Cough8.9%3.4%
Influenza7.1%3.4%
Rhinorrhea5.4%0%
Agitation5.4%1.7%
Discontinuations due to adverse reactionsa
Aggression3.6%1.7%
Irritability1.8%3.4%
aReported adverse reactions leading to discontinuation in more than one patient in either treatment group.
","
Adverse ReactionMemantineN=903
Headache8.0%
Nasopharyngitis6.3%
Pyrexia5.8%
Irritability5.4%
Discontinuations due to adverse reactionsa
Irritability1.2%
Aggression1.0%
aAt least 1% incidence of adverse reactions leading to premature discontinuation.
"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Persistent activation of central nervous system N-methyl-D-aspartate (NMDA) receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of Alzheimer’s disease. Memantine is postulated to exert its therapeutic effect through its action as a low to moderate affinity uncompetitive (open-channel) NMDA receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels. There is no evidence that memantine prevents or slows neurodegeneration in patients with Alzheimer’s disease. 12.2 Pharmacodynamics Memantine showed low to negligible affinity for GABA, benzodiazepine, dopamine, adrenergic, histamine and glycine receptors and for voltage-dependent Ca 2+ , Na + or K + channels. Memantine also showed antagonistic effects at the 5HT 3 receptor with a potency similar to that for the NMDA receptor and blocked nicotinic acetylcholine receptors with one-sixth to one-tenth the potency. In vitro studies have shown that memantine does not affect the reversible inhibition of acetylcholinesterase by donepezil, galantamine, or tacrine. 12.3 Pharmacokinetics Absorption Following oral administration memantine is highly absorbed with peak concentrations reached in about 3 to 7 hours. Memantine has linear pharmacokinetics over the therapeutic dose range. Food has no effect on the absorption of memantine. Distribution The mean volume of distribution of memantine is 9 to 11 L/kg and the plasma protein binding is low (45%). Metabolism Memantine undergoes partial hepatic metabolism. The hepatic microsomal CYP450 enzyme system does not play a significant role in the metabolism of memantine. Elimination Memantine is excreted predominantly (about 48%) unchanged in urine and has a terminal elimination half-life of about 60 to 80 hours. The remainder is converted primarily to three polar metabolites which possess minimal NMDA receptor antagonistic activity: the N-glucuronide conjugate, 6-hydroxy memantine, and 1-nitroso-deaminated memantine. A total of 74% of the administered dose is excreted as the sum of the parent drug and the N-glucuronide conjugate. Renal clearance involves active tubular secretion moderated by pH dependent tubular reabsorption. Pharmacokinetics in Specific Populations Gender Following multiple dose administration of memantine hydrochloride 20 mg daily, females had about 45% higher exposure than males, but there was no difference in exposure when body weight was taken into account. Elderly The pharmacokinetics of memantine hydrochloride in young and elderly subjects are similar. Renal Impairment Memantine pharmacokinetics were evaluated following single oral administration of 20 mg memantine hydrochloride in 8 subjects with mild renal impairment (creatinine clearance, CLcr, > 50 to 80 mL/min), 8 subjects with moderate renal impairment (CLcr 30 to 49 mL/min), 7 subjects with severe renal impairment (CLcr 5 to 29 mL/min) and 8 healthy subjects (CLcr > 80 mL/min) matched as closely as possible by age, weight and gender to the subjects with renal impairment. Mean AUC 0-∞ increased by 4%, 60%, and 115% in subjects with mild, moderate, and severe renal impairment, respectively, compared to healthy subjects. The terminal elimination half-life increased by 18%, 41%, and 95% in subjects with mild, moderate, and severe renal impairment, respectively, compared to healthy subjects. No dosage adjustment is recommended for patients with mild and moderate renal impairment. Dosage should be reduced in patients with severe renal impairment [see Dosage and Administration (2) ] . Hepatic Impairment Memantine pharmacokinetics were evaluated following the administration of single oral doses of 20 mg in 8 subjects with moderate hepatic impairment (Child-Pugh Class B, score 7 to 9) and 8 subjects who were age-, gender-, and weight-matched to the hepatically-impaired subjects. There was no change in memantine exposure (based on C max and AUC) in subjects with moderate hepatic impairment as compared with healthy subjects. However, terminal elimination half-life increased by about 16% in subjects with moderate hepatic impairment as compared with healthy subjects. No dose adjustment is recommended for patients with mild and moderate hepatic impairment. Memantine should be administered with caution to patients with severe hepatic impairment as the pharmacokinetics of memantine have not been evaluated in that population. Drug-Drug Interactions Use with Cholinesterase Inhibitors Co-administration of memantine with the AChE inhibitor donepezil hydrochloride did not affect the pharmacokinetics of either compound. Furthermore, memantine did not affect AChE inhibition by donepezil. In a 24-week controlled clinical study in patients with moderate to severe Alzheimer’s disease, the adverse event profile observed with a combination of memantine hydrochloride and donepezil was similar to that of donepezil alone. Effect of Memantine Hydrochloride on the Metabolism of Other Drugs In vitro studies conducted with marker substrates of CYP450 enzymes (CYP1A2, -2A6, -2C9, 2D6, -2E1, -3A4) showed minimal inhibition of these enzymes by memantine. In addition, in vitro studies indicate that at concentrations exceeding those associated with efficacy, memantine does not induce the cytochrome P450 isozymes CYP1A2, -2C9, -2E1 and -3A4/5. No pharmacokinetic interactions with drugs metabolized by these enzymes are expected. Pharmacokinetic studies evaluated the potential of memantine for interaction with warfarin, and buproprion. Memantine did not affect the pharmacokinetics of the CYP2B6 substrate buproprion or its metabolite hydroxy-buproprion. Furthermore, memantine did not affect the pharmacokinetics or pharmacodynamics of warfarin as assessed by the prothrombin INR. Effect of Other Drugs on Memantine Hydrochloride Memantine is predominantly renally eliminated, and drugs that are substrates and/or inhibitors of the CYP450 system are not expected to alter the metabolism of memantine. Drugs Eliminated via Renal Mechanisms Because memantine is eliminated in part by tubular secretion, co-administration of drugs that use the same renal cationic system, including hydrochlorothiazide (HCTZ), triamterene (TA), metformin, cimetidine, ranitidine, quinidine, and nicotine, could potentially result in altered plasma levels of both agents. However, co-administration of memantine hydrochloride and HCTZ/TA did not affect the bioavailability of either memantine or TA, and the bioavailability of HCTZ decreased by 20%. In addition, co-administration of memantine with the antihyperglycemic drug Glucovance ® (glyburide and metformin hydrochloride) did not affect the pharmacokinetics of memantine, metformin and glyburide. Furthermore, memantine did not modify the serum glucose lowering effect of Glucovance ® , indicating the absence of a pharmacodynamic interaction. Drugs Highly Bound to Plasma Proteins Because the plasma protein binding of memantine is low (45%), an interaction with drugs that are highly bound to plasma proteins, such as warfarin and digoxin, is unlikely."],"indications_and_usage":["1 INDICATIONS AND USAGE Memantine hydrochloride tablets are indicated for the treatment of moderate to severe dementia of the Alzheimer’s type. Memantine hydrochloride tablets are an N-methyl-D-aspartate (NMDA) receptor antagonist indicated for the treatment of moderate to severe dementia of the Alzheimer’s type. (1)"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Conditions that raise urine pH may decrease the urinary elimination of memantine, resulting in increased plasma levels of memantine. (5.1, 7.1) 5.1 Genitourinary Conditions Conditions that raise urine pH may decrease the urinary elimination of memantine resulting in increased plasma levels of memantine [see Drug Interactions (7.1) ] ."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility There was no evidence of carcinogenicity in a 113-week oral study in mice at doses up to 40 mg/kg/day (10 times the maximum recommended human dose [MRHD] on a mg/m 2 basis). There was also no evidence of carcinogenicity in rats orally dosed at up to 40 mg/kg/day for 71 weeks followed by 20 mg/kg/day (20 and 10 times the MRHD on a mg/m 2 basis, respectively) through 128 weeks. Memantine produced no evidence of genotoxic potential when evaluated in the in vitro S. typhimurium or E. coli reverse mutation assay, an in vitro chromosomal aberration test in human lymphocytes, an in vivo cytogenetics assay for chromosome damage in rats, and the in vivo mouse micronucleus assay. The results were equivocal in an in vitro gene mutation assay using Chinese hamster V79 cells. No impairment of fertility or reproductive performance was seen in rats administered up to 18 mg/kg/day (9 times the MRHD on a mg/m 2 basis) orally from 14 days prior to mating through gestation and lactation in females, or for 60 days prior to mating in males. 13.2 Animal Toxicology and/or Pharmacology Memantine induced neuronal lesions (vacuolation and necrosis) in the multipolar and pyramidal cells in cortical layers III and IV of the posterior cingulate and retrosplenial neocortices in rats, similar to those which are known to occur in rodents administered other NMDA receptor antagonists. Lesions were seen after a single dose of memantine. In a study in which rats were given daily oral doses of memantine for 14 days, the no-effect dose for neuronal necrosis was 6 times the maximum recommended human dose of 20 mg/day on a mg/m 2 basis. In acute and repeat-dose neurotoxicity studies in female rats, oral administration of memantine and donepezil in combination resulted in increased incidence, severity, and distribution of neurodegeneration compared with memantine alone. The no-effect levels of the combination were associated with clinically relevant plasma memantine and donepezil exposures. The relevance of these findings to humans is unknown."],"adverse_reactions_table":["
Adverse Reaction Placebo (N = 922) %Memantine Hydrochloride (N = 940) %
Body as a Whole
Fatigue 12
Pain 13
Cardiovascular System
Hypertension 24
Central and Peripheral Nervous System
Dizziness 57
Headache 36
Gastrointestinal System
Constipation 35
Vomiting 23
Musculoskeletal System
Back pain 23
Psychiatric Disorders
Confusion 56
Somnolence 23
Hallucination 23
Respiratory System
Coughing 34
Dyspnea 12
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION See FDA-approved patient labeling (Patient Information) . To assure safe and effective use of memantine hydrochloride, the following information and instructions provided in the patient information section should be discussed with patients and caregivers. Patients/caregivers should be instructed to follow the dose titration schedule provided by their physician or healthcare professional for memantine hydrochloride. They should be warned not to use any tablets of memantine hydrochloride that are damaged or show signs of tampering. If a patient misses a single dose of memantine hydrochloride, that patient should not double up on the next dose. The next dose should be taken as scheduled. If a patient fails to take memantine hydrochloride for several days, dosing should not be resumed without consulting that patient’s healthcare professional. Distributed by: Amneal Pharmaceuticals LLC Bridgewater, NJ 08807 Rev. 08-2023-07"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION The recommended starting dose of memantine hydrochloride tablets is 5 mg once daily. The dose should be increased in 5 mg increments to 10 mg/day (5 mg twice daily), 15 mg/day (5 mg and 10 mg as separate doses), and 20 mg/day (10 mg twice daily). The minimum recommended interval between dose increases is one week. The dosage shown to be effective in controlled clinical trials is 20 mg/day. Memantine hydrochloride tablets can be taken with or without food. If a patient misses a single dose of memantine hydrochloride tablets, that patient should not double up on the next dose. The next dose should be taken as scheduled. If a patient fails to take memantine hydrochloride tablets for several days, dosing may need to be resumed at lower doses and retitrated as described above. Specific Populations Renal Impairment A target dose of 5 mg twice daily is recommended in patients with severe renal impairment (creatinine clearance of 5 to 29 mL/min based on the Cockcroft-Gault equation). Hepatic Impairment Memantine hydrochloride tablets should be administered with caution to patients with severe hepatic impairment [see Clinical Pharmacology (12.3) ] . May be taken with or without food. (2) Initial dose is 5 mg once daily. Increase dose in 5 mg increments to a maintenance dose of 10 mg twice daily. A minimum of 1 week of treatment with the previous dose should be observed before increasing the dose. (2) Severe renal impairment: recommended dose is 5 mg twice daily. (2)"],"spl_product_data_elements":["Memantine hydrochloride Memantine MEMANTINE HYDROCHLORIDE MEMANTINE SILICON DIOXIDE CROSCARMELLOSE SODIUM MAGNESIUM STEARATE CELLULOSE, MICROCRYSTALLINE TALC D&C YELLOW NO. 10 FD&C BLUE NO. 2 FD&C YELLOW NO. 6 POLYETHYLENE GLYCOL, UNSPECIFIED POLYVINYL ALCOHOL (100000 MW) TITANIUM DIOXIDE IP173 oblong Memantine hydrochloride Memantine MEMANTINE HYDROCHLORIDE MEMANTINE SILICON DIOXIDE CROSCARMELLOSE SODIUM MAGNESIUM STEARATE CELLULOSE, MICROCRYSTALLINE TALC FERROSOFERRIC OXIDE FERRIC OXIDE YELLOW POLYETHYLENE GLYCOL, UNSPECIFIED POLYVINYL ALCOHOL (100000 MW) TITANIUM DIOXIDE IP174 oblong"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Memantine Hydrochloride Tablet USP, 5 mg: orange colored, oblong, biconvex, film-coated tablets debossed “IP 173” on one side and plain on the other side. Memantine Hydrochloride Tablet USP, 10 mg: gray colored, oblong, biconvex, film-coated tablets debossed “IP 174” on one side and plain on the other side. Tablets: 5 mg and 10 mg (3)"],"spl_patient_package_insert":["Patient Information Memantine ( meh-MAN-teen) Hydrochloride Tablets, USP Read this Patient Information that comes with memantine hydrochloride tablets before you start taking it and each time you get a refill. There may be new information. This information does not take the place of talking to your doctor about your medical condition or your treatment. What are memantine hydrochloride tablets? Memantine hydrochloride tablets are a prescription medicine used for the treatment of moderate to severe dementia in people with Alzheimer’s disease. Memantine hydrochloride tablets belong to a class of medicines called NMDA (N-methyl-D-aspartate) inhibitors. It is not known if memantine hydrochloride tablets are safe and effective in children. Who should not take memantine hydrochloride tablets? Do not take memantine hydrochloride tablets if you are allergic to memantine or any of the ingredients in memantine hydrochloride tablets. See the end of this leaflet for a complete list of ingredients in memantine hydrochloride tablets. What should I tell my doctor before taking memantine hydrochloride tablets? Before you take memantine hydrochloride tablets, tell your doctor if you: have or have had seizures have or have had problems passing urine have or have had bladder or kidney problems have liver problems have any other medical conditions are pregnant or plan to become pregnant. It is not known if memantine hydrochloride tablets will harm your unborn baby. are breastfeeding or plan to breastfeed. It is not known if memantine passes into your breast milk. Talk to your doctor about the best way to feed your baby if you take memantine hydrochloride tablets. Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Taking memantine hydrochloride tablets with certain other medicines may affect each other. Taking memantine hydrochloride tablets with other medicines can cause serious side effects. Especially tell your doctor if you take: other NMDA antagonists such as amantadine, ketamine, and dextromethorphan medicines that make your urine alkaline such as carbonic anhydrase inhibitors and sodium bicarbonate Ask your doctor or pharmacist for a list of these medicines, if you are not sure. Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine. How should I take memantine hydrochloride tablets? Your doctor will tell you how much memantine hydrochloride tablets to take and when to take it. Your doctor may change your dose if needed. Memantine hydrochloride tablets can be taken with food or without food. Do not use any memantine hydrochloride tablets that are damaged or show signs of tampering. If you forget to take one dose of memantine hydrochloride tablets, do not double up on the next dose. You should take only the next dose as scheduled. If you have forgotten to take memantine hydrochloride tablets for several days, you should not take the next dose until you talk to your doctor. If you take too much memantine hydrochloride tablets, call your doctor or poison control center at 1-800-222-1222 right away, or go to the nearest hospital emergency room. What are the possible side effects of memantine hydrochloride tablets? Memantine hydrochloride tablets may cause side effects, including: The most common side effects of memantine hydrochloride tablets include: dizziness headache confusion constipation These are not all the possible side effects of memantine hydrochloride tablets. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store memantine hydrochloride tablets? Store memantine hydrochloride tablets at room temperature between 59° to 77°F (15° to 30°C). What are the ingredients in memantine hydrochloride tablets? Memantine hydrochloride tablets: Active ingredients: memantine hydrochloride, USP Inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose and talc Inactive ingredients of tablet film coating: D&C Yellow #10, FD&C Blue #2, FD&C Yellow #6, macrogol, polyvinyl alcohol, talc, and titanium dioxide (5 mg tablets), and iron oxide black, iron oxide yellow, macrogol, polyvinyl alcohol, talc and titanium dioxide (10 mg tablets) Keep memantine hydrochloride tablets and all medicines out of the reach of children. General information about the safe and effective use of memantine hydrochloride tablets. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not take memantine hydrochloride tablets for a condition for which it was not prescribed. Do not give memantine hydrochloride tablets to other people, even if they have the same condition. It may harm them. This Patient Information leaflet summarizes the most important information about memantine hydrochloride tablets. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about memantine hydrochloride tablets that was written for healthcare professionals. For more information about memantine hydrochloride tablets, go to www.amneal.com, or call Amneal Pharmaceuticals at 1-877-835-5472. This Patient Information has been approved by the U.S. Food and Drug Administration. *Trademarks are the property of their respective owners. Distributed by: Amneal Pharmaceuticals LLC Bridgewater, NJ 08807 Rev. 08-2023-06 Dispense with Patient Information available at: documents.amneal.com/mg/ppi-memantine-hcl-tab.pdf"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary There are no adequate data on the developmental risk associated with the use of memantine hydrochloride in pregnant women. Adverse developmental effects (decreased body weight, and skeletal ossification) were observed in the offspring of rats administered memantine during pregnancy at doses associated with minimal maternal toxicity. These doses are higher than those used in humans at the maximum recommended daily dose of memantine hydrochloride [see Data] . In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown. Data Animal Data Oral administration of memantine (0, 2, 6, or 18 mg/kg/day) to rats during the period of organogenesis resulted in decreased skeletal ossification in fetuses at the highest dose tested. The higher no-effect dose for adverse developmental effects (6 mg/kg) is 3 times the maximum recommended human daily dose (MRHD) of memantine hydrochloride (20 mg) on a body surface area (mg/m 2 ) basis. Oral administration of memantine to rabbits (0, 3, 10, or 30 mg/kg/day) during the period of organogenesis resulted in no adverse developmental effects. The highest dose tested is approximately 30 times the MRHD of memantine hydrochloride on a mg/m 2 basis. In rats, memantine (0, 2, 6, or 18 mg/kg/day) was administered orally prior to and throughout mating and, in females, through the period of organogenesis or continuing throughout lactation to weaning. Decreased skeletal ossification in fetuses and decreased body weight in pups were observed at the highest dose tested. The higher no-effect dose for adverse developmental effects (6 mg/kg/day) is 3 times the MRHD of memantine hydrochloride on a mg/m 2 basis. Oral administration of memantine (0, 2, 6, or 18 mg/kg/day) to rats from late gestation throughout lactation to weaning, resulted in decreased pup weights at the highest dose tested. The higher no-effect dose (6 mg/kg/day) is approximately 3 times the MRHD of memantine hydrochloride on a mg/m 2 basis. 8.2 Lactation Risk Summary There are no data on the presence of memantine in human milk, the effects on the breastfed infant, or the effects of memantine hydrochloride on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for memantine hydrochloride and any potential adverse effects on the breastfed infant from memantine hydrochloride or from the underlying maternal condition. 8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established. Memantine failed to demonstrate efficacy in two 12-week controlled clinical studies of 578 pediatric patients aged 6 to 12 years with autism spectrum disorders (ASD), including autism, Asperger’s disorder and Pervasive Development Disorder - Not Otherwise Specified (PDD-NOS). Memantine has not been studied in pediatric patients under 6 years of age or over 12 years of age. Memantine treatment was initiated at 3 mg/day and the dose was escalated to the target dose (weight-based) by week 6. Oral doses of memantine 3 mg, 6 mg, 9 mg, or 15 mg extended-release capsules were administered once daily to patients with weights < 20 kg, 20 kg to 39 kg, 40 kg to 59 kg and ≥ 60 kg, respectively. In a randomized, 12-week double-blind, placebo-controlled parallel study (Study A) in patients with autism, there was no statistically significant difference in the Social Responsiveness Scale (SRS) total raw score between patients randomized to memantine (n=54) and those randomized to placebo (n=53). In a 12-week responder-enriched randomized withdrawal study (Study B) in 471 patients with ASD, there was no statistically significant difference in the loss of therapeutic response rates between patients randomized to remain on full-dose memantine (n=153) and those randomized to switch to placebo (n=158). The overall risk profile of memantine in pediatric patients was generally consistent with the known risk profile in adults [see Adverse Reactions (6.1)] . In Study A, the adverse reactions in the memantine group (n=56) that were reported in at least 5% of patients and at least twice the frequency of the placebo group (N=58) are listed in Table 2: Table 2: Study A Commonly Reported Adverse Reactions with a Frequency ≥ 5% and Twice That of Placebo Adverse Reaction Memantine N=56 Placebo N=58 Cough 8.9% 3.4% Influenza 7.1% 3.4% Rhinorrhea 5.4% 0% Agitation 5.4% 1.7% Discontinuations due to adverse reactions a Aggression 3.6% 1.7% Irritability 1.8% 3.4% a Reported adverse reactions leading to discontinuation in more than one patient in either treatment group. The adverse reactions that were reported in at least 5% of patients in the 12 to 48 week open-label study to identify responders to enroll in Study B are listed in Table 3: Table 3: 12 to 48 Week Open Label Lead-In study to Study B Commonly Reported Adverse Reactions with a Frequency ≥ 5% Adverse Reaction Memantine N=903 Headache 8.0% Nasopharyngitis 6.3% Pyrexia 5.8% Irritability 5.4% Discontinuations due to adverse reactions a Irritability 1.2% Aggression 1.0% a At least 1% incidence of adverse reactions leading to premature discontinuation. In the randomized withdrawal study (Study B), the adverse reaction in patients randomized to placebo (n=160) and reported in at least 5% of patients and at twice the frequency of the full-dose memantine treatment group (n=157) was irritability (5.0% vs 2.5%). Juvenile Animal Study In a study in which memantine (0, 15, 30 or 45 mg/kg/day) was orally administered to rats during the juvenile period of development (postnatal days [PND] 14 through 70), delays in sexual maturation were noted in males and females at all but the lowest dose tested, and body weight was reduced at the high dose. In rats orally administered memantine as a single dose (PND 14) or three daily doses (PND 14 to 16), neuronal lesions were observed in several areas of the brain at all but the lowest dose tested. Adverse neurobehavioral effects (decreased auditory startle habituation) were observed at the high dose. The no-effect dose for developmental toxicity was the lowest dose tested (15 mg/kg/day). In a second juvenile animal study, memantine (0, 1, 3, 8, 15, 30, and 45 mg/kg/day) was orally administered to male and female rats beginning on PND 7 and continuing for various periods during postnatal development. Because of early memantine-related mortality, the 30 and 45 mg/kg/day groups were terminated without further evaluation. Apoptosis or neuronal degeneration in the brain was observed on PNDs 8 to 17 at a dose of 15 mg/kg/day. The no-effect dose for apoptosis and neuronal degeneration was 8 mg/kg/day. In animals in which memantine (0, 1, 3, 8, or 15 mg/kg/day) was orally administered on PNDs 7 to 70, adverse neurobehavioral effects (increased locomotor motor activity, increased auditory startle response and decreased habituation, and deficit in learning and memory) were observed at all but the lowest dose tested. Effects on auditory startle persisted after drug discontinuation. The no-effect dose for developmental toxicity was the lowest dose tested (1 mg/kg/day). 8.5 Geriatric Use The majority of people with Alzheimer’s disease are 65 years and older. In the clinical studies of memantine hydrochloride the mean age of patients was approximately 76; over 90% of patients were 65 years and older, 60% were 75 years and older, and 12% were at or above 85 years of age. The efficacy and safety data presented in the clinical trial sections were obtained from these patients. There were no clinically meaningful differences in most adverse events reported by patient groups ≥ 65 years old and < 65 years old. 8.6 Renal Impairment No dosage adjustment is needed in patients with mild or moderate renal impairment. A dosage reduction is recommended in patients with severe renal impairment [see Dosage and Administration (2) and Clinical Pharmacology (12.3) ] . 8.7 Hepatic Impairment No dosage adjustment is needed in patients with mild or moderate hepatic impairment. Memantine hydrochloride should be administered with caution to patients with severe hepatic impairment [see Dosage and Administration (2) and Clinical Pharmacology (12.3) ] ."],"spl_patient_package_insert_table":["
Memantine (meh-MAN-teen) Hydrochloride Tablets, USPRead this Patient Information that comes with memantine hydrochloride tablets before you start taking it and each time you get a refill. There may be new information. This information does not take the place of talking to your doctor about your medical condition or your treatment.What are memantine hydrochloride tablets?Memantine hydrochloride tablets are a prescription medicine used for the treatment of moderate to severe dementia in people with Alzheimer’s disease. Memantine hydrochloride tablets belong to a class of medicines called NMDA (N-methyl-D-aspartate) inhibitors.It is not known if memantine hydrochloride tablets are safe and effective in children.Who should not take memantine hydrochloride tablets?Do not take memantine hydrochloride tablets if you are allergic to memantine or any of the ingredients in memantine hydrochloride tablets. See the end of this leaflet for a complete list of ingredients in memantine hydrochloride tablets.What should I tell my doctor before taking memantine hydrochloride tablets?Before you take memantine hydrochloride tablets, tell your doctor if you:have or have had seizureshave or have had problems passing urinehave or have had bladder or kidney problemshave liver problemshave any other medical conditionsare pregnant or plan to become pregnant. It is not known if memantine hydrochloride tablets will harm your unborn baby.are breastfeeding or plan to breastfeed. It is not known if memantine passes into your breast milk. Talk to your doctor about the best way to feed your baby if you take memantine hydrochloride tablets.Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements.Taking memantine hydrochloride tablets with certain other medicines may affect each other. Taking memantine hydrochloride tablets with other medicines can cause serious side effects.Especially tell your doctor if you take:other NMDA antagonists such as amantadine, ketamine, and dextromethorphanmedicines that make your urine alkaline such as carbonic anhydrase inhibitors and sodium bicarbonateAsk your doctor or pharmacist for a list of these medicines, if you are not sure.Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.How should I take memantine hydrochloride tablets?Your doctor will tell you how much memantine hydrochloride tablets to take and when to take it.Your doctor may change your dose if needed.Memantine hydrochloride tablets can be taken with food or without food.Do not use any memantine hydrochloride tablets that are damaged or show signs of tampering.If you forget to take one dose of memantine hydrochloride tablets, do not double up on the next dose. You should take only the next dose as scheduled.If you have forgotten to take memantine hydrochloride tablets for several days, you should not take the next dose until you talk to your doctor.If you take too much memantine hydrochloride tablets, call your doctor or poison control center at 1-800-222-1222 right away, or go to the nearest hospital emergency room.What are the possible side effects of memantine hydrochloride tablets?Memantine hydrochloride tablets may cause side effects, including:The most common side effects of memantine hydrochloride tablets include:dizzinessheadacheconfusionconstipationThese are not all the possible side effects of memantine hydrochloride tablets. For more information, ask your doctor or pharmacist.Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.How should I store memantine hydrochloride tablets?Store memantine hydrochloride tablets at room temperature between 59° to 77°F (15° to 30°C).What are the ingredients in memantine hydrochloride tablets?Memantine hydrochloride tablets:Active ingredients: memantine hydrochloride, USPInactive ingredients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, microcrystalline cellulose and talcInactive ingredients of tablet film coating: D&C Yellow #10, FD&C Blue #2, FD&C Yellow #6, macrogol, polyvinyl alcohol, talc, and titanium dioxide (5 mg tablets), and iron oxide black, iron oxide yellow, macrogol, polyvinyl alcohol, talc and titanium dioxide (10 mg tablets)Keep memantine hydrochloride tablets and all medicines out of the reach of children.General information about the safe and effective use of memantine hydrochloride tablets.Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not take memantine hydrochloride tablets for a condition for which it was not prescribed. Do not give memantine hydrochloride tablets to other people, even if they have the same condition. It may harm them.This Patient Information leaflet summarizes the most important information about memantine hydrochloride tablets. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about memantine hydrochloride tablets that was written for healthcare professionals.For more information about memantine hydrochloride tablets, go to www.amneal.com, or call Amneal Pharmaceuticals at 1-877-835-5472.This Patient Information has been approved by the U.S. Food and Drug Administration.*Trademarks are the property of their respective owners.Distributed by: Amneal Pharmaceuticals LLC Bridgewater, NJ 08807Rev. 08-2023-06
"],"use_in_specific_populations_table":["
Adverse ReactionMemantineN=56PlaceboN=58
Cough8.9%3.4%
Influenza7.1%3.4%
Rhinorrhea5.4%0%
Agitation5.4%1.7%
Discontinuations due to adverse reactionsa
Aggression3.6%1.7%
Irritability1.8%3.4%
aReported adverse reactions leading to discontinuation in more than one patient in either treatment group.
","
Adverse ReactionMemantineN=903
Headache8.0%
Nasopharyngitis6.3%
Pyrexia5.8%
Irritability5.4%
Discontinuations due to adverse reactionsa
Irritability1.2%
Aggression1.0%
aAt least 1% incidence of adverse reactions leading to premature discontinuation.
"],"animal_pharmacology_and_or_toxicology":["13.2 Animal Toxicology and/or Pharmacology Memantine induced neuronal lesions (vacuolation and necrosis) in the multipolar and pyramidal cells in cortical layers III and IV of the posterior cingulate and retrosplenial neocortices in rats, similar to those which are known to occur in rodents administered other NMDA receptor antagonists. Lesions were seen after a single dose of memantine. In a study in which rats were given daily oral doses of memantine for 14 days, the no-effect dose for neuronal necrosis was 6 times the maximum recommended human dose of 20 mg/day on a mg/m 2 basis. In acute and repeat-dose neurotoxicity studies in female rats, oral administration of memantine and donepezil in combination resulted in increased incidence, severity, and distribution of neurodegeneration compared with memantine alone. The no-effect levels of the combination were associated with clinically relevant plasma memantine and donepezil exposures. The relevance of these findings to humans is unknown."],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL 5 mg - 30 cnt gf ty cv"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility There was no evidence of carcinogenicity in a 113-week oral study in mice at doses up to 40 mg/kg/day (10 times the maximum recommended human dose [MRHD] on a mg/m 2 basis). There was also no evidence of carcinogenicity in rats orally dosed at up to 40 mg/kg/day for 71 weeks followed by 20 mg/kg/day (20 and 10 times the MRHD on a mg/m 2 basis, respectively) through 128 weeks. Memantine produced no evidence of genotoxic potential when evaluated in the in vitro S. typhimurium or E. coli reverse mutation assay, an in vitro chromosomal aberration test in human lymphocytes, an in vivo cytogenetics assay for chromosome damage in rats, and the in vivo mouse micronucleus assay. The results were equivocal in an in vitro gene mutation assay using Chinese hamster V79 cells. No impairment of fertility or reproductive performance was seen in rats administered up to 18 mg/kg/day (9 times the MRHD on a mg/m 2 basis) orally from 14 days prior to mating through gestation and lactation in females, or for 60 days prior to mating in males."]},"tags":[{"label":"N-methyl-D-aspartate Receptor Antagonist","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Glutamate NMDA receptor; GRIN1/GRIN2A","category":"target"},{"label":"GRIN1","category":"gene"},{"label":"GRIN2A","category":"gene"},{"label":"ACHE","category":"gene"},{"label":"N06DA52","category":"atc"},{"label":"Oral","category":"route"},{"label":"Capsule","category":"form"},{"label":"Solution","category":"form"},{"label":"Tablet","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Moderate to Severe Alzheimer's Type Dementia","category":"indication"},{"label":"Allergan","category":"company"},{"label":"Approved 2000s","category":"decade"},{"label":"Anti-Dyskinesia Agents","category":"pharmacology"},{"label":"Antiparkinson Agents","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Dopamine Agents","category":"pharmacology"},{"label":"Excitatory Amino Acid Antagonists","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"llr":564.631,"date":"","count":891,"signal":"Fall","source":"DrugCentral FAERS","actionTaken":"Reported 891 times (LLR=565)"},{"llr":518.931,"date":"","count":682,"signal":"Confusional state","source":"DrugCentral FAERS","actionTaken":"Reported 682 times (LLR=519)"},{"llr":481.566,"date":"","count":367,"signal":"Hallucination","source":"DrugCentral FAERS","actionTaken":"Reported 367 times (LLR=482)"},{"llr":359.935,"date":"","count":323,"signal":"Agitation","source":"DrugCentral FAERS","actionTaken":"Reported 323 times (LLR=360)"},{"llr":327.186,"date":"","count":235,"signal":"Aggression","source":"DrugCentral FAERS","actionTaken":"Reported 235 times (LLR=327)"},{"llr":300.854,"date":"","count":175,"signal":"Dementia","source":"DrugCentral FAERS","actionTaken":"Reported 175 times (LLR=301)"},{"llr":273.914,"date":"","count":188,"signal":"Abnormal behaviour","source":"DrugCentral FAERS","actionTaken":"Reported 188 times (LLR=274)"},{"llr":257.642,"date":"","count":431,"signal":"Somnolence","source":"DrugCentral FAERS","actionTaken":"Reported 431 times (LLR=258)"},{"llr":191.51,"date":"","count":209,"signal":"Delirium","source":"DrugCentral FAERS","actionTaken":"Reported 209 times (LLR=192)"},{"llr":191.349,"date":"","count":260,"signal":"Bradycardia","source":"DrugCentral FAERS","actionTaken":"Reported 260 times (LLR=191)"},{"llr":156.271,"date":"","count":114,"signal":"Myoclonus","source":"DrugCentral FAERS","actionTaken":"Reported 114 times (LLR=156)"},{"llr":152.502,"date":"","count":49,"signal":"Body tinea","source":"DrugCentral FAERS","actionTaken":"Reported 49 times (LLR=153)"},{"llr":150.599,"date":"","count":102,"signal":"Delusion","source":"DrugCentral FAERS","actionTaken":"Reported 102 times (LLR=151)"},{"llr":133.694,"date":"","count":306,"signal":"Gait disturbance","source":"DrugCentral FAERS","actionTaken":"Reported 306 times (LLR=134)"},{"llr":125.629,"date":"","count":260,"signal":"Syncope","source":"DrugCentral FAERS","actionTaken":"Reported 260 times (LLR=126)"}],"commonSideEffects":[{"effect":"Dizziness","drugRate":"7%","severity":"common","_validated":true},{"effect":"Headache","drugRate":"6%","severity":"common","_validated":true},{"effect":"Confusion","drugRate":"6%","severity":"common","_validated":true},{"effect":"Hypertension","drugRate":"4%","severity":"common","_validated":true},{"effect":"Coughing","drugRate":"4%","severity":"common","_validated":true},{"effect":"Constipation","drugRate":"5%","severity":"common","_validated":true},{"effect":"Vomiting","drugRate":"3%","severity":"mild","_validated":true},{"effect":"Back pain","drugRate":"3%","severity":"mild","_validated":true},{"effect":"Somnolence","drugRate":"3%","severity":"mild","_validated":true},{"effect":"Hallucination","drugRate":"3%","severity":"mild","_validated":true},{"effect":"Syncope","drugRate":"reported","severity":"unknown"},{"effect":"Cardiac failure","drugRate":"reported","severity":"unknown"},{"effect":"Anemia","drugRate":"reported","severity":"unknown"},{"effect":"Aggressive reaction","drugRate":"reported","severity":"unknown"},{"effect":"Pneumonia","drugRate":"reported","severity":"unknown"},{"effect":"Rash","drugRate":"reported","severity":"unknown"},{"effect":"Fatigue","drugRate":"2%","severity":"mild","_validated":true},{"effect":"Dyspnea","drugRate":"2%","severity":"mild","_validated":true},{"effect":"Hypotension","drugRate":"reported","severity":"unknown"},{"effect":"Cardiac arrest","drugRate":"reported","severity":"unknown"},{"effect":"Pulmonary edema","drugRate":"reported","severity":"unknown"},{"effect":"Transient ischemic attack","drugRate":"reported","severity":"unknown"},{"effect":"Cerebrovascular accident","drugRate":"reported","severity":"unknown"},{"effect":"Vertigo","drugRate":"reported","severity":"unknown"}],"contraindications":["Acute nephropathy","Disease of liver","Impaired renal function disorder"],"specialPopulations":{"Pregnancy":"There are no adequate data on the developmental risk associated with the use of memantine in pregnant women. Adverse developmental effects (decreased body weight, and skeletal ossification) were observed in the offspring of rats administered memantine during pregnancy at doses associated with minimal maternal toxicity. These doses are higher than those used in humans at the maximum recommended daily dose of memantine. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown.","Geriatric use":"The majority of people with Alzheimers disease are 65 years of age and older. In the clinical study of memantine hydrochloride extended-release, the mean age of patients was approximately 77 years; over 91% of patients were 65 years and older, 67% were 75 years and older, and 14% were at or above 85 years of age. The efficacy and safety data presented in the clinical trial sections were obtained from these patients. There were no clinically meaningful differences in most adverse reactions in patients aged 65 and over compared to younger patients.","Paediatric use":"The safety and effectiveness of memantine in pediatric patients have not been established. Memantine failed to demonstrate efficacy in two 12-week controlled clinical studies of 578 pediatric patients aged 6-12 years with autism spectrum disorders (ASD), including autism, Aspergers disorder, and Pervasive Development Disorder Not Otherwise Specified (PDD-NOS). Memantine has not been studied in pediatric patients under years of age or over 12 years of age. Memantine treatment was not shown to be effective in these patients."}},"trials":[],"aliases":[],"company":"AbbVie","patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.3192/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$117","description":"MEMANTINE 5-10 MG TITRATION PK","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=MEMANTINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:08:52.857070+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Memantine","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T02:09:00.499383+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:08:58.839902+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T02:08:52.929934+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MEMANTINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:08:59.435919+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:08:51.744331+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:08:51.744359+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL807/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:09:00.138804+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA090041","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:08:51.744362+00:00"}},"allNames":"namenda","offLabel":[],"synonyms":["memantine","alzantin","memantina","memantine hydrochloride","ebixa","namenda","maruxa","memantine HCl","nemdatine"],"timeline":[{"date":"2002-05-15","type":"positive","source":"DrugCentral","milestone":"EMA approval (H. Lundbeck A/S)"},{"date":"2003-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from FOREST LABS LLC to Allergan"},{"date":"2003-10-16","type":"positive","source":"DrugCentral","milestone":"FDA approval (Forest Labs Llc)"},{"date":"2010-06-21","type":"positive","source":"FDA Orange Book","milestone":"Namenda Xr approved — 7MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**"},{"date":"2015-04-10","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 7 manufacturers approved"}],"aiSummary":"Namenda (Memantine) is a small molecule N-methyl-D-aspartate Receptor Antagonist developed by Forest Labs LLC and currently owned by Allergan. It targets the glutamate NMDA receptor, specifically GRIN1/GRIN2A, to treat moderate to severe Alzheimer's Type Dementia. Approved by the FDA in 2003, Namenda is now off-patent with 35 generic manufacturers. Its long half-life of 60 to 80 hours and high bioavailability of 99% contribute to its efficacy. As an off-patent medication, Namenda is widely available in the market.","approvals":[{"date":"2002-05-15","orphan":false,"company":"H. Lundbeck A/S","regulator":"EMA"},{"date":"2003-10-16","orphan":false,"company":"FOREST LABS LLC","regulator":"FDA"}],"brandName":"Namenda","ecosystem":[{"indication":"Moderate to Severe Alzheimer's Type Dementia","otherDrugs":[{"name":"donepezil","slug":"donepezil","company":"Eisai Inc"}],"globalPrevalence":null}],"mechanism":{"target":"Glutamate NMDA receptor; GRIN1/GRIN2A","novelty":"Follow-on","targets":[{"gene":"GRIN1","source":"DrugCentral","target":"Glutamate NMDA receptor; GRIN1/GRIN2A","protein":"Glutamate receptor ionotropic, NMDA 1"},{"gene":"GRIN2A","source":"DrugCentral","target":"Glutamate NMDA receptor; GRIN1/GRIN2A","protein":"Glutamate receptor ionotropic, NMDA 2A"},{"gene":"ACHE","source":"DrugCentral","target":"Acetylcholinesterase","protein":"Acetylcholinesterase"},{"gene":"GRIN2B","source":"DrugCentral","target":"Glutamate NMDA receptor; GRIN1/GRIN2B","protein":"Glutamate receptor ionotropic, NMDA 2B"},{"gene":"SLC22A1","source":"DrugCentral","target":"Solute carrier family 22 member 1","protein":"Solute carrier family 22 member 1"},{"gene":"HTR3A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 3A","protein":"5-hydroxytryptamine receptor 3A"},{"gene":"GRIN3A","source":"DrugCentral","target":"Glutamate receptor ionotropic, NMDA 3A","protein":"Glutamate receptor ionotropic, NMDA 3A"}],"moaClass":"NMDA Receptor Antagonists","modality":"Small Molecule","drugClass":"N-methyl-D-aspartate Receptor Antagonist","explanation":"Persistent activation of central nervous system N-methyl-D-aspartate (NMDA) receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of Alzheimers disease. Memantine is postulated to exert its therapeutic effect through its action as low to moderate affinity uncompetitive (open-channel) NMDA receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels. There is no evidence that memantine prevents or slows neurodegeneration in patients with Alzheimers disease.","oneSentence":"Namenda works by blocking the action of glutamate at the NMDA receptor, reducing excessive neural activity associated with Alzheimer's disease.","technicalDetail":"Namenda selectively and competitively blocks the NMDA receptor, a subtype of glutamate receptor, by binding to the GRIN1 and GRIN2A subunits, thereby reducing excitotoxicity and neuronal damage associated with Alzheimer's disease."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Memantine","title":"Memantine","extract":"Memantine, sold under the brand name Namenda among others, is a medication used to slow the progression of moderate-to-severe Alzheimer's disease. It is taken by mouth.","wiki_history":"== History ==\n\n\nMemantine was first synthesized, patented, and described by Eli Lilly and Company in 1963 as an anti-diabetic agent, but it was ineffective at lowering blood sugar. By 1972, it was discovered to have central nervous system (CNS) activity, and was developed by Merz for treatment of neurological diseases, such as Parkinson's disease. Prior to this, it was theorized to directly and/or indirectly modulate the dopaminergic, noradrenergic, and serotonergic systems. However, these actions were later realized to occur at 100-fold higher concentrations than those achieved therapeutically and hence are unlikely to be involved in its effects. In 1998, NTI amended its agreement with Children's to allow Merz to take over development.\n\nIn 2000, Merz partnered with Forest to develop the drug for Alzheimer's disease in the United States under the brand name Namenda. In 2000, Merz partnered with Suntory for the Japanese market and with Lundbeck for other markets including Europe; the drug was originally marketed by Lundbeck under the name Ebixa. The cost of Namenda was $269 to $489 a month in 2012.\n\nIn February 2014, as the July 2015 patent expiration for memantine neared, Actavis, which had acquired Forest, announced that it was launching an extended release (XR) form of memantine that could be taken once a day instead of twice a day as needed with the then-current \"immediate release\" (IR) version, and that it intended to stop selling the IR version in August 2014 and withdraw the marketing authorization. This is a tactic to thwart generic competition called product hopping. However the supply of the XR version ran short, so Actavis extended the deadline until the fall. In September 2014 the attorney general of New York, Eric Schneiderman, filed a lawsuit to compel Actavis to keep selling the IR version on the basis of antitrust law.\n\nIn December 2014, a judge granted New York State its request and issued an injunction, preventing Actavis from withdrawing the IR ver","wiki_society_and_culture":"== Society and culture ==\n\n=== Recreational use ===\nRecreational use of memantine at supratherapeutic doses has been reported. It is a weak NMDA receptor antagonist and is reported to produce dissociative and phencyclidine (PCP)-like effects in animals and humans at sufficiently high doses. Even therapeutic doses have been found to produce mild dissociative-like effects in clinical studies.\n\n===Brand names===\nAs of August 2017, memantine is marketed under many brand names worldwide including Abixa, Adaxor, Admed, Akatinol, Alceba, Alios, Almenta, Alois, Alzant, Alzer, Alzia, Alzinex, Alzixa, Alzmenda, Alzmex, Axura, Biomentin, Carrier, Cogito, Cognomem, Conexine, Cordure, Dantex, Demantin, Demax, Dementa, Dementexa, Ebitex, Ebixa, Emantin, Emaxin, Esmirtal, Eutebrol, Evy, Ezemantis, Fentina, Korint, Lemix, Lindex, Lindex, Lucidex, Manotin, Mantine, Mantomed, Marbodin, Mardewel, Marixino, Maruxa, Maxiram, Melanda, Memabix, Memamed, Memando, Memantin, Memantina, Memantine, Mémantine, Memantinol, Memantyn, Memanvitae, Memanxa, Memanzaks, Memary, Memax, Memexa, Memigmin, Memikare, Memogen, Memolan, Memorel, Memorix, Memotec, Memox, Memxa, Mentikline, Mentium, Mentixa, Merandex, Merital, Mexia, Mimetix, Mirvedol, Modualz, Morysa, Namenda, Nemdatine, Nemdatine, Nemedan, Neumantine, Neuro-K, Neuroplus, Noojerone, Pertam, Polmatine, Prilben, Pronervon, Ravemantine, Talentum, Timantila, Tingreks, Tonibral, Tormoro, Valcoxia, Vilimen, Vivimex, Witgen, Xapimant, Ymana, Zalatine, Zemertinex, Zenmem, Zenmen, and Zimerz.\n\nIt is marketed in some countries as a combination drug with donepezil (memantine/donepezil) under the brand names Namzaric, Neuroplus Dual, and Tonibral MD."},"commercial":{"launchDate":"2003","_launchSource":"DrugCentral (FDA 2003-10-16, FOREST LABS LLC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1679","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=MEMANTINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MEMANTINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Memantine","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T14:18:33.875527","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:09:04.278836+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"tacrine","drugSlug":"tacrine","fdaApproval":"1993-09-09","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"donepezil","drugSlug":"donepezil","fdaApproval":"1996-11-25","patentExpiry":"Sep 23, 2037","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"rivastigmine","drugSlug":"rivastigmine","fdaApproval":"2000-04-21","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"galantamine","drugSlug":"galantamine","fdaApproval":"2001-02-28","genericCount":16,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"memantine","indications":{"approved":[{"name":"Moderate to Severe Alzheimer's Type Dementia","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Moderate to severe dementia of the Alzheimer's type"}],"offLabel":[],"pipeline":[]},"currentOwner":"Allergan","drugCategory":"mature","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"tacrine","brandName":"tacrine","genericName":"tacrine","approvalYear":"1993","relationship":"same-class"},{"drugId":"donepezil","brandName":"donepezil","genericName":"donepezil","approvalYear":"1996","relationship":"same-class"},{"drugId":"rivastigmine","brandName":"rivastigmine","genericName":"rivastigmine","approvalYear":"2000","relationship":"same-class"},{"drugId":"galantamine","brandName":"galantamine","genericName":"galantamine","approvalYear":"2001","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07470606","phase":"PHASE2","title":"Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain","status":"NOT_YET_RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2026-03","conditions":["Brain Tumor"],"enrollment":108,"completionDate":"2031-03"},{"nctId":"NCT04302870","phase":"PHASE2,PHASE3","title":"Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial","status":"RECRUITING","sponsor":"University of Edinburgh","startDate":"2020-02-27","conditions":["Motor Neuron Disease, Amyotrophic Lateral Sclerosis"],"enrollment":1150,"completionDate":"2030-12"},{"nctId":"NCT07139834","phase":"PHASE1","title":"Pattern Separation in Major Depressive Disorder","status":"NOT_YET_RECRUITING","sponsor":"Jeffrey Miller","startDate":"2026-04","conditions":["Major Depressive Disorder (MDD)"],"enrollment":30,"completionDate":"2028-08"},{"nctId":"NCT04966546","phase":"EARLY_PHASE1","title":"Targeting Spreading Depolarization After Chronic Subdural Hematoma Surgery (TASD)","status":"WITHDRAWN","sponsor":"University of New Mexico","startDate":"2022-06-01","conditions":["Chronic Subdural Hematoma"],"enrollment":0,"completionDate":"2025-12-01"},{"nctId":"NCT03553875","phase":"PHASE3","title":"Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2018-11-13","conditions":["Autism","Autism Spectrum Disorder","Nonverbal Learning Disability"],"enrollment":25,"completionDate":"2025-11-25"},{"nctId":"NCT07248228","phase":"PHASE2","title":"Memory Avoidance Whole Brain Radiotherapy vs Hippocampal Avoidance Whole Brain Radiotherapy (Athena 2 Trial)","status":"NOT_YET_RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2026-03","conditions":["Brain Metastases"],"enrollment":90,"completionDate":"2028-11"},{"nctId":"NCT07417670","phase":"PHASE4","title":"Satisfaction With Orodispersible vs Conventional Memantine in Moderate to Severe Alzheimer's Disease","status":"COMPLETED","sponsor":"Carnot Laboratories","startDate":"2024-10-04","conditions":["Alzheimer Disease"],"enrollment":105,"completionDate":"2025-08-18"},{"nctId":"NCT03527472","phase":"PHASE2","title":"Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2018-08-23","conditions":["Lupus Erythematosus, Systemic"],"enrollment":111,"completionDate":"2026-02-28"},{"nctId":"NCT04857983","phase":"PHASE2,PHASE3","title":"Memantine Augmentation of Targeted Cognitive Training in Schizophrenia","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2021-07-06","conditions":["Schizophrenia","Schizoaffective Disorder"],"enrollment":62,"completionDate":"2025-03-30"},{"nctId":"NCT07351773","phase":"NA","title":"Ultrasound-Guided Stellate Ganglion Block for Alzheimer's Disease","status":"COMPLETED","sponsor":"Taizhou Second People's Hospital","startDate":"2025-01-26","conditions":["Alzheimer's Disease(AD)","Cognitive Dysfunction"],"enrollment":40,"completionDate":"2025-11-29"},{"nctId":"NCT05063851","phase":"PHASE2","title":"The Use of Memantine for Prevention of Alzheimer's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Virginia","startDate":"2021-10-11","conditions":["Alzheimer Disease"],"enrollment":32,"completionDate":"2026-12"},{"nctId":"NCT04804644","phase":"PHASE3","title":"Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2021-06-10","conditions":["Metastatic Lung Small Cell Carcinoma","Metastatic Malignant Neoplasm in the Brain","Recurrent Lung Small Cell Carcinoma","Stage IV Lung Cancer AJCC v8"],"enrollment":200,"completionDate":"2030-07-01"},{"nctId":"NCT03550391","phase":"PHASE3","title":"Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2018-11-22","conditions":["Brain Metastases"],"enrollment":206,"completionDate":"2027-12-31"},{"nctId":"NCT03703856","phase":"PHASE4","title":"Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Diego","startDate":"2019-01-31","conditions":["Alzheimer Disease"],"enrollment":53,"completionDate":"2025-12-30"},{"nctId":"NCT05418049","phase":"PHASE2","title":"Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2022-09-08","conditions":["Fragile X Syndrome"],"enrollment":45,"completionDate":"2026-03-05"},{"nctId":"NCT04939597","phase":"PHASE3","title":"A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2022-05-10","conditions":["Central Nervous System Carcinoma"],"enrollment":192,"completionDate":"2027-09-30"},{"nctId":"NCT02144584","phase":"EARLY_PHASE1","title":"Memantine for Enhanced Stroke Recovery","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Utah","startDate":"2014-01","conditions":["Ischemic Stroke","Upper Extremity Weakness"],"enrollment":20,"completionDate":"2026-12"},{"nctId":"NCT07251023","phase":"PHASE3","title":"Efficacy and Safety of DMB-I (INN: Latrepirdine) in Patients With Alzheimer Type Dementia","status":"RECRUITING","sponsor":"Bigespas LTD","startDate":"2025-11-20","conditions":["Alzheimer Type Dementia"],"enrollment":450,"completionDate":"2027-05"},{"nctId":"NCT05013892","phase":"PHASE2","title":"NTS-WBRT in Brain Metastases","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2022-02-08","conditions":["Brain Metastases"],"enrollment":41,"completionDate":"2027-12-31"},{"nctId":"NCT05796752","phase":"PHASE2,PHASE3","title":"Behavioral Treatment and Memantine in Body Focused Repetitive Behaviors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2023-08-02","conditions":["Skin-Picking","Trichotillomania (Hair-Pulling Disorder)"],"enrollment":26,"completionDate":"2026-06"},{"nctId":"NCT06501638","phase":"PHASE2","title":"Efficacy and Safety of memanTine in the Treatment Of Frequently symPtomatic Atrial Premature Beats","status":"COMPLETED","sponsor":"Shanghai East Hospital","startDate":"2024-08-29","conditions":["Atrial Premature Beats, Contractions, or Systoles"],"enrollment":256,"completionDate":"2025-05-16"},{"nctId":"NCT07164794","phase":"PHASE2","title":"Memantine Hydrochloride in Prostate Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Bin Xu","startDate":"2025-11","conditions":["Metastatic Castration-resistant Prostate Cancer (mCRPC)","Prostate Cancer","Neuroendocrine Prostate Cancer (NEPC)"],"enrollment":15,"completionDate":"2028-06"},{"nctId":"NCT00262470","phase":"PHASE1,PHASE2","title":"Treatment of Orthostatic Intolerance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Satish R. Raj","startDate":"1997-04","conditions":["Tachycardia","Chronic Orthostatic Intolerance"],"enrollment":150,"completionDate":"2029-12"},{"nctId":"NCT06789757","phase":"PHASE2","title":"The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)","status":"RECRUITING","sponsor":"Inova Health Care Services","startDate":"2025-02-25","conditions":["Hepatocellular Carcinoma"],"enrollment":19,"completionDate":"2028-01-27"},{"nctId":"NCT05564169","phase":"PHASE3","title":"Masitinib in Patients With Mild Alzheimer's Disease","status":"NOT_YET_RECRUITING","sponsor":"AB Science","startDate":"2026-06","conditions":["Alzheimer Disease"],"enrollment":600,"completionDate":"2029-12"},{"nctId":"NCT06007846","phase":"PHASE2,PHASE3","title":"A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer","status":"RECRUITING","sponsor":"Inova Health Care Services","startDate":"2023-07-31","conditions":["Hepatocellular Carcinoma","Cirrhosis"],"enrollment":12,"completionDate":"2026-08-31"},{"nctId":"NCT06041789","phase":"PHASE2","title":"Effect of Acetylcholinesterase Inhibitors on Bone Metabolism","status":"RECRUITING","sponsor":"Duke University","startDate":"2025-02-03","conditions":["Osteoporosis"],"enrollment":45,"completionDate":"2026-11"},{"nctId":"NCT02466191","phase":"PHASE4","title":"Treatment of Pendular Nystagmus in OPT","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2015-06","conditions":["Pendular Nystagmus","Oculopalatal Tremor"],"enrollment":7,"completionDate":"2016-01"},{"nctId":"NCT01744444","phase":"PHASE2","title":"Treatment of Pendular Nystagmus With Gabapentin and Memantine in Patients With Multiple Sclerosis","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2012-11","conditions":["Pendular Nystagmus Patients With Multiple Sclerosis"],"enrollment":10,"completionDate":"2013-07"},{"nctId":"NCT01188525","phase":"PHASE1","title":"Pharmacokinetic Study to Characterize Individual Metabolic Profile","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2010-08","conditions":["Healthy Volunteers"],"enrollment":10,"completionDate":"2011-07"},{"nctId":"NCT06727773","phase":"PHASE2","title":"Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2025-05-07","conditions":["Breast Cancer","Locally Advanced Breast Cancer","Cognitive Impairment","Cognitive Decline","Cognitive Change","Breast Cancer Stage I","Breast Cancer Stage II","Breast Cancer Stage III"],"enrollment":90,"completionDate":"2028-10-31"},{"nctId":"NCT02670161","phase":"PHASE4","title":"Quality Improvement and Practice Based Research in Neurology Using the EMR","status":"ENROLLING_BY_INVITATION","sponsor":"Endeavor Health","startDate":"2016-05","conditions":["Brain Tumors","Epilepsy","Migraine","Mild Cognitive Impairment","Concussion","Multiple Sclerosis","Neuropathy","Parkinson's","Restless Legs Syndrome","Stroke"],"enrollment":3300,"completionDate":"2027-12"},{"nctId":"NCT07094438","phase":"PHASE1","title":"Study Safety and Efficacy of Deep Brain Stimulation (DBS) and Cervical Deep Lymphoid-venous Anastomosis (LVA) in Alzheimer's Disease","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-01-01","conditions":["Alzheimer Disease"],"enrollment":98,"completionDate":"2027-07"},{"nctId":"NCT06862960","phase":"PHASE2","title":"Ozanimod in Patients With Alzheimer's Disease","status":"NOT_YET_RECRUITING","sponsor":"ChenXiaoChun","startDate":"2025-07-01","conditions":["Alzheimer Disease"],"enrollment":40,"completionDate":"2027-12-30"},{"nctId":"NCT04588246","phase":"PHASE3","title":"Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery","status":"TERMINATED","sponsor":"NRG Oncology","startDate":"2021-08-05","conditions":["Anatomic Stage IV Breast Cancer AJCC v8","Metastatic Lung Non-Small Cell Carcinoma","Metastatic Lung Small Cell Carcinoma","Metastatic Malignant Breast Neoplasm","Metastatic Malignant Digestive System Neoplasm","Metastatic Malignant Neoplasm in the Brain","Metastatic Malignant Solid Neoplasm","Metastatic Melanoma","Metastatic Renal Cell Carcinoma","Recurrent Brain Neoplasm","Stage IV Lung Cancer AJCC v8","Stage IV Renal Cell Cancer AJCC v8"],"enrollment":19,"completionDate":"2024-08-06"},{"nctId":"NCT04539951","phase":"PHASE2","title":"Pragmatic Trial of Obsessive-compulsive Disorder","status":"RECRUITING","sponsor":"Shanghai Mental Health Center","startDate":"2020-09-22","conditions":["Obsessive-Compulsive Disorder"],"enrollment":1600,"completionDate":"2028-12-31"},{"nctId":"NCT01430351","phase":"PHASE1","title":"Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-09-14","conditions":["Glioblastoma","Gliosarcoma","Supratentorial Glioblastoma"],"enrollment":144,"completionDate":"2025-02-02"},{"nctId":"NCT05045950","phase":"PHASE2","title":"Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2021-11-17","conditions":["Brain Metastases"],"enrollment":53,"completionDate":"2029-05"},{"nctId":"NCT02360215","phase":"PHASE3","title":"Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases","status":"COMPLETED","sponsor":"NRG Oncology","startDate":"2015-07","conditions":["Cognitive Impairment","Metastatic Malignant Neoplasm in the Brain","Solid Neoplasm"],"enrollment":518,"completionDate":"2019-08-26"},{"nctId":"NCT06275035","phase":"PHASE3","title":"Evaluation of Memantine in the Preservation of Memory and Neurocognition Following CSI","status":"RECRUITING","sponsor":"Tata Memorial Centre","startDate":"2024-02-22","conditions":["Neurocognitive Dysfunction"],"enrollment":101,"completionDate":"2031-01"},{"nctId":"NCT06914310","phase":"PHASE2,PHASE3","title":"Memantine as an Additive Therapy in Patients With Traumatic Brain Injury","status":"NOT_YET_RECRUITING","sponsor":"Mansoura University","startDate":"2025-03-25","conditions":["Mild Traumatic Brain Injury","Moderate Traumatic Brain Injury (TBI)"],"enrollment":80,"completionDate":"2025-11-30"},{"nctId":"NCT04117178","phase":"PHASE4","title":"Monitoring Anti-Dementia Drugs by Serum Levels","status":"COMPLETED","sponsor":"Zealand University Hospital","startDate":"2020-02-04","conditions":["Dementia","Dementia With Lewy Bodies","Dementia in Parkinsons Disease","Dementia Alzheimers","Alzheimer Disease"],"enrollment":132,"completionDate":"2023-02-16"},{"nctId":"NCT05801380","phase":"","title":"Monitoring Drug Efficacy in Patients with Alzheimer's Disease","status":"RECRUITING","sponsor":"University of the Philippines","startDate":"2022-02-14","conditions":["Alzheimer Disease"],"enrollment":60,"completionDate":"2026-02-14"},{"nctId":"NCT04789915","phase":"PHASE1","title":"Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis","status":"RECRUITING","sponsor":"Bjorn H. Ebdrup","startDate":"2021-05-26","conditions":["Psychosis","Negative Symptoms With Primary Psychotic Disorder"],"enrollment":46,"completionDate":"2026-12-31"},{"nctId":"NCT04217694","phase":"EARLY_PHASE1","title":"Memantine for the Reduction of Cognitive Impairment After Radiation Therapy in Pediatric Patients With Central Nervous System Tumors","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2020-02-17","conditions":["Malignant Central Nervous System Neoplasm","Primary Central Nervous System Neoplasm"],"enrollment":18,"completionDate":"2024-08-12"},{"nctId":"NCT06679387","phase":"PHASE2","title":"\"The Effect of Memantine on the Prevention and Amelioration of Paclitaxel-induced Toxicity in Breast Cancer Patients\"","status":"RECRUITING","sponsor":"Ain Shams University","startDate":"2024-10-30","conditions":["Breast Cancer Early Stage Breast Cancer (Stage 1-3)"],"enrollment":80,"completionDate":"2025-10"},{"nctId":"NCT06594172","phase":"PHASE2","title":"Early Application of Memantine and Pioglitazone to Protect Cognitive Function After Radiotherapy","status":"NOT_YET_RECRUITING","sponsor":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","startDate":"2024-09-10","conditions":["Radiation Disease","Cognitive Impairment","Drug Effect"],"enrollment":67,"completionDate":"2027-06-30"},{"nctId":"NCT04792645","phase":"PHASE2","title":"Memantine in Body Focused Repetitive Behaviors","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2021-06-15","conditions":["Trichotillomania (Hair-Pulling Disorder)","Dermatillomania"],"enrollment":100,"completionDate":"2022-07-08"},{"nctId":"NCT06337994","phase":"PHASE3","title":"Memantine Hydrochloride for Treatment of Cognitive Dysfunction Due to Traumatic Brain Injury","status":"COMPLETED","sponsor":"Assiut University","startDate":"2024-01-01","conditions":["Treatment of Cognitive Deficits After Traumatic Brain Injury"],"enrollment":60,"completionDate":"2024-08-01"},{"nctId":"NCT04538066","phase":"PHASE2","title":"Bryostatin Treatment of Moderately Severe Alzheimer's Disease","status":"COMPLETED","sponsor":"Neurotrope Bioscience, Inc.","startDate":"2020-08-30","conditions":["Alzheimer Disease"],"enrollment":122,"completionDate":"2022-11-16"},{"nctId":"NCT01333865","phase":"PHASE4","title":"A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2010-01","conditions":["Autism Spectrum Disorders"],"enrollment":25,"completionDate":"2014-07"},{"nctId":"NCT01972074","phase":"PHASE3","title":"Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2015-02-17","conditions":["Autism Spectrum Disorder"],"enrollment":84,"completionDate":"2018-05-07"},{"nctId":"NCT05664464","phase":"PHASE1,PHASE2","title":"Glutamate Inhibitors in Glioblastoma","status":"RECRUITING","sponsor":"University of Zurich","startDate":"2023-01-01","conditions":["Glioblastoma"],"enrollment":120,"completionDate":"2026-12"},{"nctId":"NCT04698525","phase":"PHASE3","title":"Comparative Study Between Valproate and Memantine in the Prophylactic Management of Episodic Migraine.","status":"COMPLETED","sponsor":"Universidad Autonoma de San Luis Potosí","startDate":"2019-02-15","conditions":["Migraine Headache"],"enrollment":33,"completionDate":"2020-01-15"},{"nctId":"NCT03670095","phase":"PHASE1","title":"Study in Healthy Subjects to Compare Two Tablet Formulations of Memantine (Ebixa®) in Fasted and Fed Conditions","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2018-08-28","conditions":["Healthy"],"enrollment":64,"completionDate":"2018-12-24"},{"nctId":"NCT00401167","phase":"PHASE4","title":"Memantine for Agitation and Aggression in Severe Alzheimer's Disease","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2006-11","conditions":["Alzheimer's Disease"],"enrollment":31,"completionDate":"2010-01"},{"nctId":"NCT05647473","phase":"PHASE2","title":"Efficacy, Safety and Response Predictors of Adjuvant Astragalus for Cognition in Orthostatic Hypotension","status":"UNKNOWN","sponsor":"Fujian Medical University Union Hospital","startDate":"2024-02-20","conditions":["Orthostatic Hypotension","Alzheimer Disease"],"enrollment":66,"completionDate":"2025-05-30"},{"nctId":"NCT01872598","phase":"PHASE3","title":"Masitinib in Patients With Mild to Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"AB Science","startDate":"2012-01","conditions":["Alzheimer Disease"],"enrollment":721,"completionDate":"2020-12"},{"nctId":"NCT03194906","phase":"PHASE2","title":"Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-11-07","conditions":["Glioma of Brain","Craniopharyngioma","Ependymoma","Germ Cell Tumor"],"enrollment":34,"completionDate":"2023-06-28"},{"nctId":"NCT02304302","phase":"PHASE2","title":"Down Syndrome Memantine Follow-up Study","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2014-10","conditions":["Down Syndrome","Intellectual Disability"],"enrollment":160,"completionDate":"2020-07-22"},{"nctId":"NCT02580305","phase":"PHASE2","title":"SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study","status":"COMPLETED","sponsor":"Suven Life Sciences Limited","startDate":"2015-09","conditions":["Alzheimer's Disease"],"enrollment":564,"completionDate":"2019-11-07"},{"nctId":"NCT05834231","phase":"PHASE1,PHASE2","title":"Efficacy of Memantine in Prevention of Oxaliplatin-induced Peripheral Neurotoxicity","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2023-08","conditions":["Cancer"],"enrollment":60,"completionDate":"2024-10"},{"nctId":"NCT04033419","phase":"PHASE2","title":"Memantine for Prevention of Cognitive Decline in Patients With Breast Cancer","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2019-09-25","conditions":["Cognitive Decline","Chemo-brain"],"enrollment":55,"completionDate":"2022-04-04"},{"nctId":"NCT05807165","phase":"","title":"HF-SRT vs. HS-WBRT in Treating Patients With Brain Oligometastases","status":"NOT_YET_RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2023-08-01","conditions":["Brain Oligometastases"],"enrollment":115,"completionDate":"2026-07-31"},{"nctId":"NCT05804279","phase":"PHASE1","title":"Pharmacokinetics of BPDO-1603 or BPDO-16031 and BPDO-16033 Administration in Healthy Adults","status":"COMPLETED","sponsor":"Hyundai Pharm","startDate":"2022-12-28","conditions":["Healthy"],"enrollment":24,"completionDate":"2023-03-14"},{"nctId":"NCT03860597","phase":"PHASE4","title":"Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2018-04-01","conditions":["Schizophrenia","Schizo Affective Disorder","Schizoaffective Disorder","Healthy"],"enrollment":42,"completionDate":"2021-03-31"},{"nctId":"NCT00646204","phase":"PHASE4","title":"Namenda (Memantine) for Non-motor Symptoms in Parkinson's Disease","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2006-04","conditions":["Parkinson's Disease"],"enrollment":40,"completionDate":"2009-03"},{"nctId":"NCT02118727","phase":"PHASE2","title":"Therapy in Amyotrophic Lateral Sclerosis (TAME)","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2018-11-07","conditions":["Amyotrophic Lateral Sclerosis","Frontal Temporal Dementia"],"enrollment":89,"completionDate":"2021-07-22"},{"nctId":"NCT01555697","phase":"PHASE1,PHASE2","title":"Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2014-07","conditions":["Schizophrenia"],"enrollment":80,"completionDate":"2019-06-01"},{"nctId":"NCT05538507","phase":"PHASE2","title":"Efficacy of Chinese Traditional Medicine \"Smart Soup\" in Cognition and Behavior Regulation in Alzheimer's Disease","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2022-06-01","conditions":["Alzheimer Disease","Mild Cognitive Impairment"],"enrollment":180,"completionDate":"2024-06"},{"nctId":"NCT05531383","phase":"NA","title":"Effect of Early Memantine Administration on Outcome of Patients With Moderate to Severe Traumatic Brain Injury","status":"UNKNOWN","sponsor":"Minia University","startDate":"2021-11-26","conditions":["Traumatic Brain Injury"],"enrollment":70,"completionDate":"2024-07-09"},{"nctId":"NCT05532644","phase":"","title":"Correlation of P-glycoprotein Polymorphisms With Microbial Metabolites in Patients With Alzheimer's Disease on Medication","status":"UNKNOWN","sponsor":"Aristotle University Of Thessaloniki","startDate":"2022-09","conditions":["Alzheimer Disease"],"enrollment":135,"completionDate":"2024-09"},{"nctId":"NCT03986424","phase":"PHASE3","title":"Local Study of Akatinol Memantine in VaD in Russia","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2018-01-23","conditions":["Vascular Dementia"],"enrollment":130,"completionDate":"2022-06-01"},{"nctId":"NCT05430867","phase":"PHASE4","title":"Efficacy and Safety of Memantine and Sodium Oligomannate in Patients With Moderate to Severe Alzheimer's Disease","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2022-07-01","conditions":["Treatment","Efficacy","Safety","Alzheimer Disease"],"enrollment":150,"completionDate":"2024-12-31"},{"nctId":"NCT03954613","phase":"PHASE4","title":"Evaluation of the Contribution of Regular Cognitive Exercises to Treatment in Patients With Alzheimer's Disease","status":"UNKNOWN","sponsor":"Neutec Ar-Ge San ve Tic A.Ş","startDate":"2020-10-15","conditions":["Alzheimer Disease","Cognitive Change"],"enrollment":198,"completionDate":"2024-03-01"},{"nctId":"NCT05321680","phase":"NA","title":"Withdrawal of Antidementia Drugs in Advanced Dementia (WADAD)","status":"COMPLETED","sponsor":"Centro Hospitalar De São João, E.P.E.","startDate":"2021-03-01","conditions":["Dementia"],"enrollment":16,"completionDate":"2022-03-20"},{"nctId":"NCT00371059","phase":"PHASE4","title":"Memantine for Agitation in Dementia","status":"COMPLETED","sponsor":"East Kent Hospitals University NHS Foundation Trust","startDate":"2007-09","conditions":["DEMENTIA"],"enrollment":153,"completionDate":"2009-09"},{"nctId":"NCT03709888","phase":"","title":"Memantine XR and Pregabalin for Chemotherapy-Induced Peripheral Neuropathy","status":"COMPLETED","sponsor":"Saint John's Cancer Institute","startDate":"2016-07-09","conditions":["Chemotherapy-induced Peripheral Neuropathy"],"enrollment":20,"completionDate":"2021-04-29"},{"nctId":"NCT03779672","phase":"PHASE4","title":"Memantine for Epileptic Encephalopathy","status":"COMPLETED","sponsor":"Kenneth Myers, MD","startDate":"2019-02-07","conditions":["Epileptic Encephalopathy, Childhood-Onset"],"enrollment":30,"completionDate":"2022-02-08"},{"nctId":"NCT05102045","phase":"NA","title":"The Effects of Repetitive Transcranial Magnetic Stimulation in Patients With Alzheimer's Disease","status":"COMPLETED","sponsor":"Istanbul Medipol University Hospital","startDate":"2016-09-01","conditions":["Alzheimer Disease"],"enrollment":27,"completionDate":"2017-06-01"},{"nctId":"NCT01535040","phase":"PHASE2","title":"Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2012-08-01","conditions":["Breast Cancer","Colorectal Cancer","Lung Cancer","Prostate Cancer","Tobacco Use Disorder"],"enrollment":130,"completionDate":"2014-02-01"},{"nctId":"NCT03565809","phase":"","title":"Quality of the Management of Diabetes in Elderly People With Dementia in France","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2017-05-02","conditions":["Alzheimer Disease"],"enrollment":87816,"completionDate":"2018-12-31"},{"nctId":"NCT03221894","phase":"","title":"A Retrospective Study to Investigate the Additive Effectiveness of Chinese Herbal Medicine in Alzheimer's Disease","status":"COMPLETED","sponsor":"Dongzhimen Hospital, Beijing","startDate":"2017-07-15","conditions":["Alzheimer Disease"],"enrollment":120,"completionDate":"2021-07-31"},{"nctId":"NCT05015595","phase":"PHASE3","title":"Memantine for Refractory OCD Patients","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2021-09-01","conditions":["Obsessive-Compulsive Disorder"],"enrollment":20,"completionDate":"2022-12-31"},{"nctId":"NCT00880685","phase":"PHASE2","title":"Memantine in the Treatment of Kleptomania","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2009-03","conditions":["Kleptomania"],"enrollment":12,"completionDate":"2012-06"},{"nctId":"NCT02080364","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease","status":"TERMINATED","sponsor":"vTv Therapeutics","startDate":"2015-04","conditions":["Alzheimer's Disease"],"enrollment":880,"completionDate":"2018-06-01"},{"nctId":"NCT02811627","phase":"EARLY_PHASE1","title":"Predicting Treatment Response to Memantine in Autism Using Magnetic Resonance Spectroscopy","status":"COMPLETED","sponsor":"University of Missouri-Columbia","startDate":"2016-06","conditions":["Autism Spectrum Disorder"],"enrollment":10,"completionDate":"2021-04"},{"nctId":"NCT03988803","phase":"PHASE1","title":"A Study in Healthy Men and Women to Test Which Effects Memantine and BI 425809 Have on Each Other","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-07-17","conditions":["Healthy"],"enrollment":16,"completionDate":"2019-10-30"},{"nctId":"NCT04801342","phase":"PHASE2","title":"Neurocognitive Outcome of Bilateral or Unilateral Hippocampal Avoidance WBRT With Memantine for Brain Metastases","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2021-04-01","conditions":["Metastatic Malignant Neoplasm to Brain"],"enrollment":72,"completionDate":"2025-02-28"},{"nctId":"NCT01585168","phase":"PHASE2","title":"Functional Neuroimaging of Alcoholism Vulnerability (PIT)","status":"COMPLETED","sponsor":"Yale University","startDate":"2011-12","conditions":["Healthy"],"enrollment":71,"completionDate":"2016-05"},{"nctId":"NCT04035798","phase":"PHASE2,PHASE3","title":"add-on Low Dose Memantine in Middle-to-old Aged Bipolar II Disorder Patients","status":"UNKNOWN","sponsor":"National Cheng-Kung University Hospital","startDate":"2019-08-01","conditions":["Bipolar II Disorder"],"enrollment":120,"completionDate":"2022-07-31"},{"nctId":"NCT04737967","phase":"PHASE2,PHASE3","title":"The Potential Protective Role of Venlafaxine Versus Memantine in Paclitaxel Induced Peripheral Neuropathy","status":"UNKNOWN","sponsor":"Mendel AI","startDate":"2021-02-15","conditions":["Oncology Pain","Chemotherapy-induced Peripheral Neuropathy"],"enrollment":60,"completionDate":"2021-10-01"},{"nctId":"NCT00652457","phase":"PHASE4","title":"Study of Memantine to Treat Huntington's Disease","status":"COMPLETED","sponsor":"Jody Corey-Bloom, MD, PhD","startDate":"2004-11-23","conditions":["Huntington's Disease"],"enrollment":50,"completionDate":"2009-10-28"},{"nctId":"NCT04687566","phase":"PHASE2,PHASE3","title":"Dextromethorphan, Memantine Monotherapy, or Combined Use of Dextromethorphan and Memantine in Amphetamine Addiction","status":"UNKNOWN","sponsor":"National Cheng-Kung University Hospital","startDate":"2020-08-11","conditions":["Amphetamine Addiction","Pharmacotherapy"],"enrollment":120,"completionDate":"2024-07-31"},{"nctId":"NCT03729128","phase":"PHASE1,PHASE2","title":"Add-on Low Dose Dextromethorphan and Memantine in Patients With Amphetamine-type Stimulants Use Disorder","status":"COMPLETED","sponsor":"Tzu-Yun Wang","startDate":"2018-07-24","conditions":["Stimulants Use Disorder"],"enrollment":85,"completionDate":"2020-08-31"},{"nctId":"NCT00545974","phase":"PHASE4","title":"Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2007-10","conditions":["Frontal Lobe Dementia","Frontotemporal Lobe Dementia","Semantic Dementia"],"enrollment":81,"completionDate":"2012-12"},{"nctId":"NCT02535611","phase":"PHASE3","title":"Evaluation of Memantine Versus Placebo on Ischemic Stroke Outcome","status":"COMPLETED","sponsor":"Mazandaran University of Medical Sciences","startDate":"2015-10","conditions":["Ischemic Stroke","Excitotoxicity","Memantine"],"enrollment":47,"completionDate":"2017-09"},{"nctId":"NCT03560245","phase":"PHASE2","title":"A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine","status":"COMPLETED","sponsor":"Neurotrope Bioscience, Inc.","startDate":"2018-06-20","conditions":["Alzheimer Disease"],"enrollment":108,"completionDate":"2019-07-25"},{"nctId":"NCT03959124","phase":"NA","title":"Deep Brain Stimulation for Alzheimer's Disease","status":"UNKNOWN","sponsor":"Buddhist Tzu Chi General Hospital","startDate":"2020-04-06","conditions":["Alzheimer Disease","Dementia, Alzheimer Type","Deep Brain Stimulation"],"enrollment":30,"completionDate":"2021-09-30"},{"nctId":"NCT03858270","phase":"PHASE3","title":"Inhibition of α-synuclein Cell-cell Transmission by NMDAR Blocker, Memantine","status":"UNKNOWN","sponsor":"Wayne State University","startDate":"2019-04-01","conditions":["Parkinson Disease"],"enrollment":50,"completionDate":"2023-07-01"}],"_emaApprovals":[{"date":"2002-05-15","status":"Authorised","company":"H. Lundbeck A/S"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Capsule, Solution, Tablet","formulations":[{"form":"CAPSULE","route":"ORAL","productName":"Namzaric"},{"form":"CAPSULE, EXTENDED RELEASE","route":"ORAL","productName":"MEMANTINE HYDROCHLORIDE"},{"form":"CAPSULE, EXTENDED RELEASE","route":"ORAL","productName":"Memantine Hydrochloride"},{"form":"CAPSULE, EXTENDED RELEASE","route":"ORAL","productName":"Memantine and Donepezil Hydrochlorides Extended-release"},{"form":"CAPSULE, EXTENDED RELEASE","route":"ORAL","productName":"Memantine hydrochloride"},{"form":"CAPSULE, EXTENDED RELEASE","route":"ORAL","productName":"memantine hydrochloride"},{"form":"CAPSULE, EXTENDED RELEASE","route":"ORAL","productName":"Memantine Hydrochloride"},{"form":"CAPSULE, EXTENDED RELEASE","route":"ORAL","productName":"Namenda\n XR"},{"form":"CAPSULE, EXTENDED RELEASE","route":"ORAL","productName":"NamendaXR"},{"form":"SOLUTION","route":"ORAL","productName":"MEMANTINE"},{"form":"SOLUTION","route":"ORAL","productName":"Memantine Hydrochloride"},{"form":"TABLET","route":"ORAL","productName":"MEMANTINE HYDROCHLORIDE"},{"form":"TABLET","route":"ORAL","productName":"Memantine"},{"form":"TABLET","route":"ORAL","productName":"Memantine Hydrochloride"},{"form":"TABLET","route":"ORAL","productName":"memantine"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000148824","MMSL":"169783","NDDF":"006597","UNII":"W8O17SJF3T","VUID":"4021409","CHEBI":"CHEBI:64312","VANDF":"4021409","INN_ID":"3952","RXNORM":"236685","UMLSCUI":"C0025242","chemblId":"CHEMBL807","ChEMBL_ID":"CHEMBL1699","KEGG_DRUG":"D04905","DRUGBANK_ID":"DB01043","PDB_CHEM_ID":" 377","PUBCHEM_CID":"4054","SNOMEDCT_US":"406457005","IUPHAR_LIGAND_ID":"4253","SECONDARY_CAS_RN":"41100-52-1","MESH_DESCRIPTOR_UI":"D008559"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2003-","companyName":"Forest Labs Llc","relationship":"Original Developer"},{"period":"present","companyName":"Allergan","relationship":"Current Owner"},{"period":"2002","companyName":"H. Lundbeck A/S","relationship":"EMA Licensee"}],"pharmacokinetics":{"source":"FDA label","halfLife":"60 to 80 hours","bioavailability":"99%","fractionUnbound":"0.526%"},"publicationCount":4719,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"N06DA52","allCodes":["N06DA52","N06DA53","N06DX01"]},"biosimilarFilings":[],"originalDeveloper":"Forest Labs Llc","recentPublications":[{"date":"2026 Apr","pmid":"41885326","title":"Incidence of amyloid-related imaging abnormalities and health resource utilization in patients with Alzheimer disease receiving monoclonal antibody treatments: A real-world evidence study.","journal":"Journal of managed care & specialty pharmacy"},{"date":"2026 Mar 24","pmid":"41877006","title":"Posterior insular cortex hyperactivation drives vestibular migraine and comorbid anxiety.","journal":"The journal of headache and pain"},{"date":"2026 Mar 30","pmid":"41874250","title":"Comparison table: Drugs for Alzheimer's disease dementia.","journal":"The Medical letter on drugs and therapeutics"},{"date":"2026 Mar 30","pmid":"41874248","title":"Drugs for dementia.","journal":"The Medical letter on drugs and therapeutics"},{"date":"2026 Mar 17","pmid":"41863240","title":"Diamonds for the Mind: Exploring the Potential of Adamantane against Alzheimer's Disease.","journal":"Mini reviews in medicinal chemistry"}],"combinationProducts":[{"brandName":"Namzaric","ingredients":"donepezil + memantine"}],"companionDiagnostics":[],"genericManufacturers":35,"_genericFilersChecked":true,"genericManufacturerList":["Ajanta Pharma Ltd","Alembic","Amneal Pharms","Ani Pharms","Apotex","Aurobindo Pharma Ltd","Chartwell","Chartwell Molecular","Dr Reddys Labs Ltd","Hetero Labs Ltd V","Hikma","Jubilant Generics","Lannett Co Inc","Lupin Ltd","Macleods Pharms Ltd","Orbion Pharms","Ph Health","Pointview Hldings","Puracap Labs Blu","Puracap Pharm Llc","Renata","Rising","Sciegen Pharms","Seton Pharms","Strides Pharma","Sun Pharm","Teva Pharms","Torrent","Unichem","Upsher Smith Labs","Vitruvias","Yichang Humanwell","Yiling","Zydus Lifesciences","Zydus Pharms"],"status":"approved","companyName":"Allergan","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"2003","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2003-10-16T00:00:00.000Z","mah":"FOREST LABS LLC","brand_name_local":null,"application_number":""},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":16,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:09:04.278836+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}